annual reportthreeyears briefworldwide change dollars millions except per share figures sales customers net earnings cash dividends paid shareholders equity percent return average shareholders equity per share net earnings basic diluted cash dividends paid shareholders equity market price yearend close average shares outstanding millions basic diluted number employees thousands net earnings earnings per share include inprocess research development iprd charges million diluted earnings per share related acquisitions tibotecvirco nv obtech medical ag excluding impact charges net earnings increased net earnings earnings per share include million diluted earnings per share million diluted earnings per share respectively related iprd alza merger costs iprd net restructuring gains detailed discussion charges refer note notes consolidated financial statements description company contents johnson johnson billion sales letter shareholders worlds comprehensive broadly editorial section based manufacturer health care products board directors well provider related services committees board consumer pharmaceutical medical devices diagnostics markets johnson johnson corporate officers company group chairmen approximately employees corporate governance managements responsibility operating companies countries managements discussion analysis around world selling products consolidated financial statements countries notes consolidated financial statements cover independent auditors report malvern pennsylvania facility centocor segments business geographic areas inc new monoclonal antibody manufacturing summary operations statistical data facility joyce salpan manufacturing principal global affiliates associate foreground chaley larson senior worldwide family companies supervisor work help company double capacity produce remicadeinfliximab corporate shareholderinvestor information rheumatoid arthritis crohns disease patientsletter shareholders william cweldon chairman chief executive officer trong performance across segments company made necessary investments broadly based health care business capital expenditures support growth enabled johnson johnson achieve excep business strong free cash flow tional growth sales earnings billion provided fuel billion share repurchase record sales billion represented growth program acquisitions billion dividend operational growth curren increase referred earlier maintaining cy exchange rates contributing favorable effect companys outstanding triple credit rating first time seven years setting results context historical per record net earnings billion increase formance good year company excluding special charges led diluted earnings consistent long tradition growth per share growth fact last time achieve year year strong performance board directors sales growth great depression increased quarterly dividend april earnings growth remarkably consistent th consecutive year per quarter per doubledigit gains excluding special charges quarter increase past years cash flow operations continued one important ways encourage strong billion net approximate longterm consistent performance invest ly million tax invested various ments science technology indeed theme pension plans year ensure continued report year delivering promise strength relevant monitor free cash technology evidence belief flow portion operating cash flow remains investments fundamental sustaining james tlenehan vice chairman president establishing leadership positions permit us deliver acquired orapharma inc specialty pharmaceutical superior returns shareholders make mean company recently announced agreement acquire ingful difference health care people around world scios inc californiabased company product business segments throughout treat congestive heart failure important biophar worldwide operations face future opti maceutical pipeline evidence strategy mism commitment see many opportuni hope conclude acquisition second quarter ties continued growth development pursue year growth managing set broad princi decentralized management system also reflected ples maintaining broadly based health care business strong performance gives us focus stressing decentralized system management sense ownership local markets dedicated managing long term foundation values empowered management groups quickly espoused credo pursue local avenues opportunity extraordinary record consistent performance focus managing company long term result broad base human health care increasingly sustains performance emphasizes emphasize collaborations across technology plat investment future importance true inno forms enable proprietary positions cypher vation invested billion research sirolimuseluting stent promising example col development previous year laborative outcomes achieve time since pharmaceutical companies alone recognize potential seize opportunity research development staff grown external licensing arrangements strategic acqui recently announced pending acquisition sitions second quarter completed acquisition dimensional pharmaceuticals outstanding organi tibotecvirco nv belgium organization focused zation strategic complement pharma developing antiviral treatments early year ceutical discovery development research capabilities also engaged threeyear capital invest drug administration fda approval levaquin ment program begun million additional indication treatment nosocomi worldwide research development across al pneumonia second common hospitalacquired business segments making major enhancements infection extending leadership contraceptives additions facilities information market launched ortho evra first contracep technology infrastructure accelerate ability tive patch ortho tricyclenlo new lowdose bring new products market deliver oral contraceptive promise technology without product challenges finally less significantly sustain consis europe small subset patients taking eprex tent performance culture based subcutaneously chronic renal failure tak strong system values expect highest standards ing erythropoietins saw rare serious ethical behavior throughout global organization occurrence pure red cell aplasia immune achieved us assumes responsibility lead response based continuing investigation ership integrity guided pursuit issues implemented labeling change eprex credo embodiment values provides patients important information place years safest method administration recog fourpart strategic business model broadly nize potential effect growth eprex based human health care decentralized managed result actions urgent priority ensure long term foundation strong values safety patients rely product served us well yielding enduring record consistent medical devices diagnostics segment growth performance continues light way leading medical device business world repre future sents worldwide sales saw operational terms business performance growth strong sales growth successful year johnson johnson pharma achieved across major areas business including ceuticals largest fastest growing cordis circulatory disease management products three business segments worldwide pharmaceu depuy orthopaedic joint reconstruction spinal tical sales grew operational growth products ethicon wound care surgical sports medicine importantly growth area reflects womens health products lifescan blood glucose performance number key products procrit monitoring products ethicon endosurgery minimally eprex treatment anemia continued invasive surgery products orthoclinical diagnostics realize new potential around world although professional diagnostic products vistakon dispos entry key competitor us market man able contact lenses date increased focus clinical competitive advan cypher sirolimuseluting stent cordis tages going forward strong performers great example collaboration devices risperdal antipsychotic pharmaceutical segments available filed application use treatment bipolar countries around world fda approval disorder remicade treatment rheumatoid united states hoped soon although reim arthritis crohns disease bursement system europe constrained growth reviewed indications immunemediated dis extent pleased level market eases duragesic transdermal patch chronic acceptance product breakthrough tech pain aciphexpariet proton pump inhibitor nology significant impact health gastrointestinal disorders approved wellbeing patients two additional indications symptomatic gastroin developments included fda approval testinal reflux disease common cause vicrylplus suture ethicon suture peptic ulcers topamax antiepileptic antibacterial coating reduce potential surgi filed monotherapy treatment cal site infection acquisition obtech medical ag prevention migraine headaches adults markets europes leading treatment morbid year company also received us food obesity integration ethicon endosurgery business favorable fda panel recommendation two board members retire april independenceibotmobility system dr maxine singer member board since hope bring market robert wilson recently served vision care franchise outstanding year senior vice chairman board bobs contribu particularly broad acceptance acuvue tions first pharmaceutical businesses later penetration japanese market day corporate management board direction acuvue growing popularity acuvue instrumental growth last decade colours tinted contact lens greatly missed consumer segment continues deliver solid per begin another year enthusiasm formance representing total sales achieving exciting times move ahead agenda focused operational growth combined skin key strategic imperatives development care businesses neutrogena aveeno clean innovative product solutions collaborations across clearand rocsaw strong growth particularly broadly based health care business flawless execution emphasis superior science technology leadership acknowledge great heritage nutritionals category notably splenda stand see promise future yet nocalorie sweetener market leader fulfilled build foundation move table top sweetener category ingredient strength strength recognizing enormous brands sold countries dedication power workforce viactivcalcium chews new bandaidbrand strong grateful efforts liquid bandage helped wound care franchise achieve continued allegiance shareholders strong growth one example collaboration together give us confidence harness proven technology case prescription indeed deliver promise technology device dermabondtopical skin adhesive improve health care adaptation new market application backdrop confident well positioned future performance evidence shift recent years businesses firmly rooted science technology higher margin proprietary businesses offer opportunity sus william c weldon tained profitable growth continue seize chairman board competitive advantages capitalize opportunities chief executive officer offer promise better health care people around world strength leadership diversity experiences background bring organiza tion key continued success thank ded icated board directors counsel provide james lenehan regard april welcomed david satcher vice chairman board md phd companys board directors president dr satcher former surgeon general united states director national center primary care morehouse school medicine regret accepted resignation john snow march named cabinet position secretary treasury united states appreciate guidance pro vided since member board wish well service country acknowledge outstanding contributions delivering promise technology urs company driven mission improve human health care science technology see promise fulfill mission deliver promise collaboration research process improvement dedication committed workforce common pursuit better health care people around worldygolonhcet fo esimorp eht gnireviled remicade infliximaba mono clonal antibody treatment rheumatoid arthritis developed centocoris biologic therapy approved usfda induce maintain clinical remission patients moderate severe crohns diseasetanabe seiyakultdlaunched remicade japan crohns disease patients janssencilag ortho biotech european sales forcesare max imizing pharmaceutical sales marketing techniques using new customer relationship management technologies plan sales calls share importantdata peers better serve customers johnson johnsonthrough orthomcneil pharmaceutical janssen pharmaceuticais among founding members together rx prescription savings program thatprovides savings eligible medicare enrollees prescription products combining proprietary oros delivery technology yearsprocrit alza ascending dose profileconcerta epoetin alfa also marketed methylphenidate hcl cii mcneil consumer specialty eprex erypo outside us pharmaceuticals first extendedrelease formulation helped millions patients overcome anemia associated methylphenidate treatment attention deficit hyperactivity cancer chemotherapypre disorder minimizes ups downs blood levels dialysis kidney diseaseazttreated patient experience stimulant medications taken several times hivand certain elective surgeries day lasting hours concerta demonstrates power eprex erypo also indicated oros transform standard pharmaceutical tablet treatanemia dialysis patients advanced drug delivery system uses osmosis natural move ment water semipermeable membrane make oral drug administration controlled precise convenient incorporated commercialized products including concerta us fda approved concerta mg extendedrelease tablets offering greater dosing flexibility concerta also approved many countries europe latin america asia shown katya alvarez successful college student adhd symptom control concerta gets help heading back dormito ry dad julio alvarez mcneil district manager acquisition tibotecvirco expands drug discovery research development capabilitiesparticularly field antiinfectivesthe belgiumbased biopharma ceutical company brought johnson johnson several promising compounds development treatment hiv number innovative disease management tools tibotec applies latest techniques ultrahigh throughput screening antiviral profiling molecular biology drug design discovering developing new antiinfective drugs company programs focusing potential drugs active drugresistant strains hiv including two products early clinical development additionally early stage research programs concentrating treatments infectious diseases including hepatitis c virco develops markets advanced diagnostic tools based pharmacogenomic principles clinical management viral infections including hiv featured left right gery dams senior scientist koen van acker research fellow paula mckenna director diagnostic lab operations w e create new options health care across range disciplines pharmaceutical agents medical devicesdiagnostics delivery platforms consumer products although broadly based focus human health care compounds derived small molecules smart technologies compensate frailties disease patented formulations serve growing consumer needs alza focus sophisticated drug delivery technologybased products expanded theconstruction manufacturing facility cashelireland products incorporate drug delivery technologies alza widely commercialized com panies inside outside johnson johnson deliver unique patient advantages cashel plant squarefoot facility ample room future expansion adds critical capacity manufacture products growing european marketplace time reduces pressure production supply chain operations united states improving efficiency enhancing service cashel site represents shared com mitment alza johnson johnson engineering technical resources create manufacturing center excellence drug delivery technology says robert strickland managing director cashel facility shown company expects begin shipping product facility third quarter delivering promise technology aciphex rabeprazole sodium copromoted eisai incand janssen pharmaceutica incand prescribed gastroesophageal reflux diseasewas approved usfda partof first sevenday treatmentfor hpylori infectionthe mostcommon cause peptic ulcers usfda approved levaquin levofloxacin tabletsinjection levaquin levofloxacin dextrose injection mg treatmentof nosocomial hospitalacquired pneumonia intricatestateoftheartcomputing research net levaquin fluoroquinolone antiinfective orthomcneil work laboratory connects major research facilities pharmaceuticalinc throughoutthe companywas created johnson johnson clinical study anti networking computing services ncs facilitate product design epilepsy medication topamax creation alleviating roadblocks geographic topiramatetopiramate capsules time zone differences throughout company rooms various tablets sprinkle capsules johnson johnson locations around world global researchers use orthomcneil pharmaceutical incdemonstrated significant advanced communication tools highdefinition visualization effecton controlling seizures model science ways typically visible human newlydiagnosed patientseven eye grid collaboration connects persons diverse loca used standalone therapy tions via internet research network leadingedge technol ogy enables massive amounts data exchanged time expected help johnson johnson businesses reduce time takes bring product marketplace james regina vice presi dent technology engineering development ncs left stuart kippelman director advanced technologies research pictured front prototype collaboration system ncs ygolonhcet fo esimorp eht gnireviled regulatory agenciesof germany ukwere firstto approve risperdal consta risperidone janssencilag firstatypical antipsychotic available form long acting injectionthis form approved european coun tries new zealandmexico israel korea johnson johnson acquired orapharmainca specialty pharma ceutical company focused developmentand commercialization uniquepatented therapeutics orapharma operate partof personal products company provides entry oral care professional marketplace initial focus treatmentand prevention periodontal disease process excellence major focus atjohnson johnson resulted important solutionsto wide range formi dable challenges one solution successfully implemented ortho tricyclen lonorgesti increasing number patients began raising concerns mateethinyl estradiol ortho mcneil pharmaceuticalincis key product marketed janssen duragesicfentanyl transder newlowdose version mal system medicated patch providing three days relief mostprescribed birth control pill patients chronic pain apparently detaching skin usortho tricyclen process excellence team janssen included members norgestimateethinyl estradiol johnson johnson companies charged resolving lower level estrogenthe new version highly effective problem team led director process excellence chris herbine left director marketing jim eckhardt right followed ukregulatory authority specific analytical improvement methodology concluded granted janssencilag ltdan exten sion license durogesic detaching problem mostly related patients improperly applying fentanyl transdermal system patch designed program centered educational materials beyond cancer include types clearly described proper way apply patch plan severechronic painalso ensure patients caregivers health care professionals janssen pharmaceutical kkin japan launched product use product access information result called durotep cancer pain percent reduction complaint rate twoyear period improvement customer satisfaction contributing sub stantial increase duragesic sales centocor double manufacturing capacity remicade infliximab new malvern pennsylvaniafacility fully operational mid remicade monoclonal antibody used treat patients rheumatoid arthritis patients gastrointestinal disorder crohns disease hundreds thousands patients treat ed worldwide remicade fully capable meeting current market demand remicade centocor poised maximize potential product markets throughout world facility shown valerie ulicny monitors processes one largest advanced mammalian cell culture bio pharmaceutical bulk production centers world addition malvern operation centocor produces therapeutic agents using monoclonal antibody technology leiden netherlands w e employ dedicated people give stateoftheart facilities work worldwide provide resources need become workforce future focus imperatives enable us make meaningful contribution collaboration across disciplinary lines unique advantage broadly based company acquisition inverness medical limited iml strengthened ability lifescan serve global diabetes market helped enhance companys commit ment improve quality life people diabetes inverness facility manufactures test strips used diabetes patients blood glucose selftesting part lifescan onetouch ultra induo onetouchultrasmart smartscanand euroflashsystems due need expand research development capabilities production capacity iml recently initi ated new construction part substantial capital investment facilities inverness scotland enabling iml bolster pro duction test strips increase new product development pictured checking quality card strips thomas stevenson manu facturing team leader left nigel spiller manufacturing director delivering promise technology stringent quality production standards pharmaceutical manufacturer janssencilag applied new cypher sirolimuseluting stentgiving cordis unique advantage first market worldwide available countries throughout world expected available year lap disc hand access device united states cypher stent reported reduce rate introduced ethicon endosurgery reblockage coronary arteries bare metal stents current treat used handassisted laparoscopic ment clogged arteries prevent reblockage occurs surgery itis enabling less invasive less painful surgical procedures approximately percent worlds stent patients trial follow also reduces hospitalization eight months binary instent restenosis reblockage recovery time compared occurred percent cases cypher stent traditional surgery used addition latina italy facility janssencilag surgifoam absorbablegelatin francesca finocchiaro pictured inspects coated stents cypher powder johnson johnson stent manufactured janssen facility beerse belgium wound managementis another plant beginning partnership device phar hemostatic powder thatcomes maceutical technologies led development cypher selfcontained sterile mixing vessel itcan spread shaped con stent made possible diversity interests human health form irregular surfaces stop care distinct johnson johnson companies bleeding fast prolene patchpolypropylene mesh ethicon productsan innovative threedimensional device repair abdominal wall herniasoffers simplestreamlined insertion techniqueitis designed preventmigration recur renceand provides new dimen sion comfortand healing monarch spinesystemfrom depuy acromed comprehensive pedicle screwrod hook system immobilization stabilization spinal segments treat mentof acute chronic instabili ties deformities thoracic lumbar sacral spine p eht gnireviled ethicon endosurgeryexpanded mammotome breastbiopsy system productline intro ducing four new probe sizeswhich increases number lesions thatcan biopsied using minimallyinvasive technique watchband incisionintro duced cardiovationsa division ethiconinccombines multiple technologies enable endo scopic radial artery harvesting results significantly smaller scar thatcan hidden behind watchband offers potential less trauma largeincision surgery japan represents importantglobal market ethicon endosurgerycompany percutaneous transluminal coronary group chairman karen licitraright angioplasty ptca balloons manufactured lpga hall famer kathy whitworth green atthe th cordisthe aqua tptca balloon catheter annual ethicon endosurgery pink available markets united states ribbon lpga proam benefitin developed cooperation cardiologists supportof breastcancer research japan makes easier interventional cardiolo gynecarea division ofethiconinc gists cross treat challenging lesions among introduced new productto com unique attributes balloon innovative plementits established gynecare tvt tensionfree supportfor sealing technology makes efficient incontinence productlinethe delivery balloon designed navigate gynecare tvt abdominal smoothly tortuous anatomy tapered guidesoffers broader group tip aids crossing tight lesions aqua health care professionals options balloon catheter first launched japan treatthe growing female stress urinary incontinence market benelux region europe released world markets excluding united states throughout first half cordis associates donna sakaguchi shinichi miyata confer dr taro saito interventional cardiologist kumamoto research drives discovery devel opment investment facilities technologies make possible discovery development new health care solutions normal pressure hydrocephalus nph afflicts people usand thousands worlda form hydrocephalus characterized abnormal accumu lation cerebrospinal fluid ventricles brain devastating disease difficult diagnose often goes untreated causes symptoms difficulty walking mild dementia uri nary incontinence nph treated many cases symptoms reversed codman hakimprogrammable shunt system codman world leader neurosurgical implants surgical products introduction codman hakim programmable valve system uses programmer adjust pressure valve non invasively cranial shunt implanted need surgical adjustment eliminated one nph patient received codman hakim programmable valve bob fowler right dallas texas meets michael mcintyre senior product directorhydrocephalus codman acquisition swissbased obtech medical ag provides ethicon endosurgery opportunity offer surgeons another minimallyinvasive alternativeexpand extensive line products used treatment morbid obesity strengthen competitive position advanced technologies exemplifies way ethicon endosurgery continually seeks respond diversified needs surgeons patients swedish adjustable gastric band sagb inflatable band fitted around uppermost part stomach laparo scopic surgery creating small pouch food intake greatly reduced resulting weight loss physician able adjust bands inner diameter time injecting removing fluid access port although yet available us sagb widely used throughout europe treatment morbid obesity since also marketed countries dr karl miller left hallein austria team including dietician monika zeiner seated work company representative franz buchner right provide education support patients honing processes put flawless execution within grasp make investments efficient possible enable us fulfill mission improve quality life delivering promise technology onetouch ultrasmartblood glucose monitoring system lifescana meter electronic logbook oneautomatically organizes blood glucose results importantdiabetes informa tion meaningful charts graphs help people better man age diabetes advanced diagnosticsystems ads division orthoclinical diagnostics focused high impactproducts human cancer diagnosismonitoringscreening patientmanagementdavid atkins general manager molecular diagnostics group within ads applies genomic tools ordinarily used drug discovery molecular diagnostic productdevelopment promogran matrix wound dressingfrom johnson johnson wound managementwas intro introduction first prepackaged sterile duced chronic wound bandage development firstever dressing thatcombines oxidized regenerated cellulose collagen antibacterial suturethe medical device companies johnson itis indicated treatmentof johnson ushered many new generations surgical care exuding wounds includingbutnot limited todiabeticvenous yearend launch vicrylplus antibacterial suture pressure ulcers ethicon products introduced new era devices may help reduce risk complications associated surgery vitro stud preservation minimally invasive unicompartmental knee ies demonstrate vicryl plus effective bacteria depuy orthopaedics enables often cause surgical site infection united states alone restoration softtissue balance surgical site infections occur annually cost assure natural function billion medical system percent alignmentitis system integrating fixed mobile surgical site infections occur incision site vicryl plus bearing components minimally antibacterial suture handling characteristics vicryl invasive knee reconstruction suture worlds widely used absorbable suture howard scalzo jr staff engineer punam aggarwal managernew product integration shown examine active zone around suture laboratory dish p eht gnireviled viactiv softcalciumchewsfrom mcneil nutritionals avail able milk chocolatemochaccino caramel orange cream flavors two chews provide percentof daily value calcium splenda caloriesweetener mcneil nutritionals become leading low calorie sweetener usgrocery marketsplenda found prod ucts countries vistakon division johnson johnson vision careincintroduced acuvue colours brand contact lenseswhich offer natural colors superior comfortlaunched glob ally acuvue coloursis independence technology delivers inaugural already number two lens commitment five years ago bring new freedom uscosmetic tintsegment people mobilityrelated disabilitiesin late new toothbrush launched orthopaedic rehabilitation devices panel us food personal products companyreach drug administration fda unanimously recommended approval maxis clinically proven reduce gingivitisits rubber bristles independenceibotmobility system fda massage gums multilevel approval hoped around second quarter bristles clean hardtoreach places independence ibot mobility system navigate uneven terrain help preventgum disease climb stairs ramps balance standing height two neutrogena menis clinically wheels also late acquisition led recent introduction proven line skin care products independenceiglidemanual assist wheelchair respond mens specific skin uses proprietary technology continuously monitor amount care needsthe line contains razor defense skin clearing prod force needed propel chair different types terrain users ucts designed turn problem skin propel chair carpet similarly difficult terrain much healthier looking skin less effort traditional manual wheelchairs may reduce incidence common problems rotator cuff injury carpal tunnel syndrome united states estimated million people use wheelchairs shown sandy salerno occu pational therapist independence technology acquaints william scelza independence iglide manual assist wheelchair w e cultivate leadership people committed making measurable difference take corporation future global contributor better health care brand expansion customer development strategies help johnson johnson worldwide baby products business continue growfor example global retail operations dynamic latin america market focus five key franchises consumer business region holds number one two market position around world innovation results insights consumer preferences serve expand markets grow sales recent launches products johnsonsbaby shampoo curly hair available several latin america countries appropriate family members exemplify importance market expansion line exten sions brandbuilding creative merchandising con cepts pictured retail outlet buenos aires argentina marita messuti trade marketing manag er consumer business johnson johnson de argentina sa cel company seen seized promise technology improve quality life company researchers work worlds leading skin care scientists bring marketplace array technologydriven skin care products fulfill consumers needs every age johnson johnson primarily competes traditional skin care arena includes facial body hand care continu ous growth within franchise achieved johnson johnson consumer products company comprehensive adult skin care franchise clean clear aveeno roc purposeand shower showerbrands steady stream beneficial skin care products neutrogena ensure skin care prod ucts meet customer needs company conducts extensive market research creates innovative marketing programs example wb clean clear casting call sponsored conjunction wb television network showcasing clean clear products helped make brand leading teen skin care line us marketing staff members including john weinstock group product director clean clear us pictured worked beauty consultants traveling exhibits delivering promise technology revolutionary liquid bandage changing way consumers treat minor cuts scrapeswas introduced johnson johnson consumer products company bandaidbrand liquid bandage provides superior protection optimal healing stays hardtocover areas like fingers tylenol sinus tylenol knuckles bandage creates clear seal keeps water colddaynightconvenience packs germs help prevent infection promote quick healing mcneil consumer specialty stays naturally sloughs wound heals bandaid pharmaceuticals contain brand liquid bandage contains octyl cyanoacrylate base one package day night formula relieve day night material found dermabondtopical skin adhesive prescription time symptoms sinus pain device marketed ethicon products manufactured colds one convenientbox closure medical corporation used physicians close wounds johnson johnson consumer incisions place stitches staples dermabond adhesive acts products companysigned agree barrier seals bacteria lead infection mentto acquire compeed ethicon products introduced thicker formulation dermabond products business worldwide provides better control physicians michael e haddadeast coloplastasthe acquisition ern division manager pictured checks major retail accounts shelf provides worldwide access comprehensive line patented facing new bandaidbrand liquid bandage technologies well platform develop strong european wound care presence simply stuffy andsimply coughare single ingredient products children mcneil consumer specialty pharmaceu ticalscontaining thatmedicine needed specific condition one nasal decongestantand cough suppressant coughs due colds aveeno positivelyradiant daily moisturizer johnson johnson consumer products company uses patented technology based effectof small proteins soy diminishing appear ance skin pigmentationclinically provenitgives skin even tone smooth texture una gran familiacampaign tylenol acetaminophen fea tures employees mcneil con sumer specialty pharmaceuticals las piedraspuerto ricoin television commercial didntdrive million milesor planted acres treeswe would reduce emissions amount saved years solar panels neutrogenathe square feet panels largest com mercial solar rooftop installation california generate enough elec tricity day power homes developed close johnson johnson pediatric partnership city los angeles reduce operating institutellcis dedicated advancementof maternal chil costs monthly energy consumption company per drens health carein partnerships cent senaka nanayakkara neutrogena director facilities engineer health care professionalsdevel ing angelina galiteva director strategic planning los angeles opmental specialists interna department water power discuss initiative project tional organizationsthe institute undertakes initiatives thathelp neutrogena exemplifies johnson johnson commitment shape future childrens health use renewable energy resources burning fossil fuels largest manmade source greenhouse gases atmosphere human health dependson health planetand com contribute climate change johnson johnson energy conser pany recognizes links conser vation goals established aggressive targets reducing green vation earths biological house gas emissions past decade carbon dioxide emissions diversitypartnerships increased modest percent nature conservancy world wildlife fund advance thatpurpose improve quality life mcneil canada achieved imme diate percentreduction co emissions conver sion company fleetvehicles percentethanolbased fuels availablethe company rec ommends use efficientfuels employees campaign nursings futuresm sponsored johnson johnson address critical shortage nursesis usinitiative recruit retain nurses nursing facul tyitincludes national advertising fundraising eventsrecruiting mate rials website surgical eye expeditions johnson johnson provided funds selfsustaining eye clinic serve poor uninsured juarezmexicosince opening julythe clinic examined patientsabout percent return surgery upon completion clinic bove remember longstanding commitments customersour employees shareholders communities live work yalejohnson johnson physician scholars international health program puts physicians hospi tals countries limited health technology resourcesparticipants learn application profes sion developing countries sharing medical knowledge people johnson johnson funding enabled yale expand offering physicians residency training leading us hospi tals universities offer international opportunities experienced career physicians academic year nearly physicians enrolled program since program began doctors including kimberly curseen md shown left tracyann clarke md right par ticipated according yale study programs alumni exhibit caring attitudes toward health care delivery especially poor underserved communities nonparticipant counter parts research shown patients respond favorably treatment doctors compassionate sensitive board directors william c weldon david satcher md leo f mullin chairman board director national chairman chief directors center primary care executive officer chief executive officer delta air lines inc robert j darretta henry b schacht ann jordan executive vice president director senior advisor former director finance information lucent technologies inc social services management chief department chicago financial officer lyingin hospital committees board audit benefits compensation audit committee composed benefits committee composed compensation committee entirely nonemployee directors entirely nonemployee directors composed entirely nonemployee helps board oversee companys reviews management vari directors reviews compensation accounting reporting practices ous retirement pension health philosophy policy nonboard recommends independent public welfare plans cover substantial management compensation committee accountants appointment ly employees companys respect executive compen board reviews performance domestic operations employees sation fringe benefits monitors adequacy internal certain international subsidiaries compensation matters committee accounting practices procedures committee also monitors also administers companys stock controls reviews significant performance trusts option plans determines changes accounting policies pension funds invested compensation members executive committee james g cullen chairman maxine f singer phd chairman arnold g langbo arnold g langbo chairman leo f mullin james g cullen henry b schacht gerard n burrow md maxine f singer phd james lenehan president chief president carnegie vice chairman executive officer institution washington board directors sea research foundation president robert n wilson judah folkman md arnold g langbo james g cullen senior vice chairman senior associate retired chairman retired president board directors surgery director board chief chief operating officer childrens hospital executive officer bell atlantic corporation professor cell biology kellogg company harvard medical school finance process performance evaluation ann jordan chairman finance committee exercises committees board russell c deyo management authority board additionally committee reviews judah folkman md intervals board company 's management succes david satcher md meetings sion plans executive resources science technology william c weldon chairman henry b schacht chairman science technology advisory robert j darretta gerard n burrow md committee composed board mem james lenehan ann jordan bers companys vice president leo f mullin science technology advises board scientific matters include nominating corporate governance public policy major internal projects interaction nominating corporate public policy advisory committee academic outside research governance committee composed composed board members organizations acquisition entirely nonemployee directors companys vice president administra technologies products responsible overseeing corporate tion reviews companys policies governance matters reviewing possible programs practices public gerard n burrow md chairman candidates board membership health issues regarding environ judah folkman md recommending nominees election ment health safety raymond w ruddon md phd committee also responsible employees advises makes david satcher md evaluating function perfor recommendations board maxine f singer phd mance board overseeing issues corporate officers company group chairmen corporate officers william c weldon russell c deyo john papa chairman board directors vice president administration treasurer chief executive officer executive committee chairman executive committee brian perkins michael j dormer worldwide chairman james lenehan worldwide chairman consumer pharmaceuticals vice chairman board directors medical devices nutritionalsgroup president executive committee executive committee executive committee roger fine per peterson md phd robert n wilson vice president general counsel chairman research development senior vice chairman executive committee pharmaceuticals group board directors executive committee vice chairman executive committee colleen goggins worldwide chairman larry g pickering j andrea alstrup consumer personal care group vice president corporate development vice president advertising executive committee christine poon michael j carey thomas gorrie phd worldwide chairman vice president human resources vice president pharmaceuticals group government affairs policy executive committee stephen j cosgrove corporate controller joann heffernan heisen raymond w ruddon md phd vice president vice president science technology robert j darretta chief information officer executive vice president executive committee michael h ullmann finance information management secretary chief financial officer willard nielsen associate general counsel executive committee vice president public affairs company group chairmen robert w croce executive committee johnson william dearstyne jr johnson principal management carlos gottschalk group responsible operations walter hak allocation companys resources karen licitra addition several executive committee dennis n longstreet members serve chairmen group eric p milledge operating committees com patrick mutchler prised managers represent key david norton operations within groups well gerald ostrov management expertise specialized jose v sartarelli phd functions committees oversee joseph c scodari coordinate activities domestic curt selquist international companies related pericles p stamatiades consumer pharmaceutical gerard vaillant medical devices diagnostics businesses nicholas j valeriani operating management company carol webb headed chairman president general manager managing director reports directly line executive group operating committee corporate governance managements responsibility johnson johnson governed values set forth audit committee board directors composed credo created general robert wood johnson solely independent directors financial knowledge principles guided us many years continue experience provide appropriate oversight review set tone integrity entire company levels internal control matters key accounting financial employees johnson johnson committed ethical reporting issues audit committee regular basis principles embodied credo principles addition independent auditors general counsel woven fabric company vice president internal audit regularly meet private ses credo values extend accounting financial sionswith audit committee discuss results reporting responsibilities shareholders work including observations adequacy internal finan investors management johnson johnson cial controls quality financial reporting confirm responsible integrity objectivity accompanying properly discharging responsibilities rele financial statements related information also vant matters responsible ensuring financial data reported accurately regularly review business results strategic prior manner facilitates understanding data ities executive committee continuously involved evidence commitment responsibility review financial results well developing maintain strong system internal accounting controls standing strategies key initiatives long term growth encourage strong effective corporate governance intent ensure maintain objectivity business board directors continuously review business results assessments constructively challenge approach business strategic choices focus financial stewardship opportunities issues monitor business results corporate staff professionally trained internal audi related controls tors travel worldwide monitor system internal consolidated financial statements financial data accounting controls designed provide reasonable follow responsibility management statements assurance assets safeguarded transactions prepared conformity accounting principles events recorded properly internal controls generally accepted united states america include include selfassessments internal external audit amounts based best judgments commit reviews operating companies also require ted providing timely accurate understandable informa management teams operating companies certify tion shareholders compliance policy business conduct systematic program ensure compliance policies employee levels pricewaterhousecoopers llp companys independent auditor engaged audit financial statements pricewaterhousecoopers llp maintains understanding william c weldon robert j darretta internal controls conducts tests auditing chairman board executive vice president procedures considered necessary circumstances express directors chief finance information opinion independent auditors report executive officer management chief financial officer table contents managements discussion analysis overview organization description segments operating results financial position capital resources matters audited consolidated financial statements consolidated balance sheets consolidated statements earnings consolidated statements equity consolidated statements cash flows notes consolidated financial statements independent auditors report segments business geographic areas summary operations statistical data managements discussion analysis results operations financial condition overview description business record sales billion exceeded sales company approximately employees worldwide billion marked th year consecutive engaged manufacture sale broad range prod positive sales growth growth led strong ucts health care field company sells products performances pharmaceutical medical devices virtually countries world companys primary diagnostics segments interest historically currently products balance sheet remains strong cash generated related human health wellbeing operations billion cash dividends per share paid company organized principle decentralized shareholders increased rep management executive committee johnson johnson resented th consecutive year cash dividend increases principal management group responsible opera company continues one companies tions allocation resources company triple credit rating committee oversees coordinates activities domestic international companies span consumer organization pharmaceutical medical devices diagnostics segments managements objectives international subsidiary exceptions companys objective achieve superior levels capital managed citizens country located efficient profitable growth accomplish companys product lines company competes compa management operates business consistent certain nies large small located united states strategic principles proven successful time america abroad competition strong lines without end company participates growth areas human regard number size competing companies health care committed attaining leadership positions involved competition research involving development inthese growth segments development innova improvement new existing products tive products services approximately billion processes particularly significant results time sales invested research development rec time product process obsolescence development ognizing importance ongoing development new new improved products important companys suc differentiated products services cess areas business competitive environment companys system management operates decen requires substantial investments continuing research tralized basis operating companies located inmultiple sales forces addition winning retention countries company views management philosophy customer acceptance companys consumer products asset fundamental success broadly based involves heavy expenditures advertising promotion business also fosters entrepreneurial spirit combining description segments theextensive resources large organization ability react quickly local market changes challenges consumer businesses managed long term order sustain consumer segments principal products personal leadership positions achieve growth provides care including nonprescription drugs adult skin hair care enduring source value shareholders products baby care products oral care products first aid prod unifying management team companys dedi ucts womens health products nutritional products cated employees achieving objectives johnson products marketed principally general public dis johnson credo credo provides common set values tributed wholesalers directly independent serves constant reminder companys responsibilities chain retail outlets throughout world major brands customers employees communities shareholders skin hair care line products include neutrogena company believes basic principles along roc aveeno clean clear johnsons ph piz overall mission improving quality life people every buinand sundownsun care products shower enable johnson johnson continue among showerpersonal care products major brands leaders health care industry thecounter line products include broad family result corporate governance issues atcer tylenolacetaminophen products adult childrens tain companies government lawmakers enacted sarbanes motrinanalgesic products imodium mylantaand oxley act protect investors improving accuracy pepcidacid controller johnson johnson merck reliability corporate disclosures light legislation consumer pharmaceuticals co major brands womens company established documented formal health care line products include carefree stayfree process around already existing internal controls like obtampons monistat major brands baby care annual certification compliance management line products include johnsonsbaby line products policy business conduct company continues evaluate penatenand natusanbaby care products major enhance internal control processes additionally first aid products include bandaidbrand adhesive company continues maintain strong ethical environment bandages compeed major oral care products include using johnson johnson credo overall guide reachbrand toothbrushes major products nutrition als product line include splenda noncaloric sugar substi tute viactivcalcium chews benecolfood products pharmaceutical medical devices diagnostics pharmaceutical segments principal worldwide franchises medical devices diagnostics segment includes broad antifungal antiinfective cardiovascular contraceptive range products used direction health care dermatology gastrointestinal hematology immunology professionals products include ethicons wound care neurology oncology pain management psychotropic central surgical sports medicine womens health products ethicon nervous system urology fields products endosurgerys minimally invasive surgical products cordis cir distributed directly wholesalers health culatory disease management products lifescans blood glucose care professionals use prescription general public monitoring products orthoclinical diagnostics professional prescription drugs antifungal field include nizoral diagnostic products depuys orthopaedic joint reconstruction ketoconazole sporanoxitraconazole terazolter spinal products vistakons disposable contact lenses conazole daktarintmmiconazole nitrate antifungal products used principally professional fields products prescription drugs antiinfective field include physicians nurses therapists hospitals diagnostic laboratories floxinofloxacin levaquinlevofloxacin prescrip clinics acquisitions medical devices diagnostics tion drugs inthe cardiovascular field include retavase segment recent years integral part reteplase recombinant biologic cardiology care product ongoing process transform medical supply business one treatment acute myocardial infarction improve blood serving arange higher technology medical specialties flow heart reoproabciximab treatment operating results acute cardiac disease prescription drugs contraceptive field include sales ortho evranorelgestrominethinyl estradiol transdermal worldwide sales increased billion system orthonovumnorethindroneethinyl estradiol compared increases tricilestnorgestimateethinyl estradiol sold sales three largest distributors amerisourcebergen us asortho tricyclen group oral contraceptives corp mckesson hboc cardinal distribution accounted prescription drugs dermatology field include retina respectively total revenues excluding microtretinoin dermatological cream acne prescrip impact foreign currencies worldwide sales increased tion drugs gastrointestinal field include aciphex price increases rabeprazole sodium proton pump inhibitor treating accounted approximately growth erosive gastroesophageal reflux disease gerd duodenal respectively ulcersfrom company derives service revenue sales domestic companies billion product copromoted inthe us eisai imodium billion billion represents loperamide hcl antidiarrheal motiliumdomperidone increases agastrointestinal mobilizer remicadeinfliximab sales international companies billion novel monoclonal antibody treatment certain crohns billion billion represents disease patients remicadeis also indicated treatment increases rheumatoid arthritis excluding impact foreign currency fluctuations prescription drugs hematology field include procrit past three years sales international companies epoetin alfa sold outside us eprex biotechnology increased derived version human hormone erythropoietin last five years annual compound growth rate sales stimulates red blood cell production prescription drugs excluding impact foreign currency fluctuations immunology field include orthocloneoktmuromonab annual compound growth rate sales year cd reversing rejection kidney heart liver period transplants prescription drugs neurology field include geographic areas throughout world posted opera topamaxtopiramate reminylgalantamine tional gains excluding effect exchange rate stugeroncinnarizine prescription drugs oncology fluctuations us dollar foreign currencies field include doxildoxorubicin anticancer treatment sales increased europe western ergamisollevamisole hydrochloride colon cancer drug hemisphere excluding us asiapacific leustatincladribine hairy cell leukemia africa regions including impact currency fluctuations prescription drugs psychotropic central nervous sys sales increased europe asiapacific tem field include antipsychotic drugs risperdalrisperidone africa decreased western hemisphere exclud haldolhaloperidol concertamethylphenidate ing us company achieved annual compound attention deficithyperactivity disorder prescription drugs growth rate worldwide sales year period pain management field include duragesicfentanyl trans since domestic sales growing rate dermal system sold abroad durogesic transdermal international sales growing rate excluding patch chronic pain ultracettmtramadol hydrochlo impact foreign currency fluctuations annual compound ride analgesic moderate moderately severe pain growth rate year period prescription drugs urology field include ditropan xl oxybutynin treatment overactive bladder consumer segment sales billion second quarter company completed increase increase consumer acquisition tibotecvirco nv approximately mil segment sales prior year operational growth lion tibotecvirco nv privatelyheld biopharmaceutical currency negatively impacting sales growth company focused developing antiviral treatments sev domestic sales increased international sales gains eral promising compounds development treatment local currency offset negative currency infectious diseases including hiv impact resulting total international growth fourth quarter company received consumer sales achieved strong growth skin care products us food drug administration fda approval neutrogena clean clearand aveeno band levaquinlevofloxacin additional indication aid wound care products well mcneil nutritionals treatment nosocomial pneumonia second common splendasweetener products viactivcalcium chews hospitalacquired infection company also filed several new consumer segment sales billion drug applications fda include topamaxtop increase domestic sales increased iramate prevention migraine headaches adults international sales gains local currency well use monotherapy treatment epilepsy offset negative currency impact resulting total currently approved adjunctive treatment levaquinfor growth consumer segment sales bil fiveday treatment communityacquired pneumonia lion increase domestic sales increased risperdalrisperidone adjunctive monotherapy international salesgains local currency treatments bipolar disorder offset negative currency impact resulting also fourth quarter company announced total decrease definitive agreement acquire orapharma inc specialty pharmaceutical segment sales billion pharmaceutical company focused development com increase including growth domestic mercialization unique therapeutics oral health care prod sales total growth international sales includes ucts acquisition provide entry oral health positive effect currency increase professional marketplace providing synergistic line pre pharmaceutical segment sales prior year due vention treatment products maintain periodontal health operational increases currency positively impacting sales transaction valued approximately million net growth cash closed first quarter sales growth reflects strong performance pharmaceutical segment sales billion procriteprex treatment anemia remicade total increase including growth treatment rheumatoid arthritis crohns disease domestic sales operationally international sales increased risperdal antipsychotic medication duragesic partially offset negative currency impact transdermal patchfor chronic pain topamaxan anti resulting total growth pharmaceutical segment epileptic medication sales procriteprexaccounted sales billion increase total company revenues including growth domestic sales operationally interna johnson johnson markets prescription drugs tional sales increased offset nega around world sales generated outside tive currency impact resulting total decrease sales united states thirtythree drugs sold company sales growth partially offset restricted access sales excess million excess million propulsidin number markets around world rate growth sales procritand eprexwas worldwide sales billion medical slowed latter half result new competition devices diagnostics segment represented increase procrit sales growth may also affected currency impact sales growth rare reports pure red cell aplasia prca chronic renal total increase also operational sales increase failure crf patients administered eprexsubcutaneously prior year domestic sales international companys ongoing investigation prca crf patients sales increased prior year indicates occurrence prca continues rare strong sales growth achieved major fran chises within segment cordis circulatory disease manage ment products depuys orthopaedic joint reconstruction spinal products ethicons wound care surgical sports medicine womens health products lifescans blood glucose monitor ing products ethicon endosurgerys minimally invasive surgical products orthoclinical diagnostics professional diagnostic products vistakons disposable contact lenses third quarter company announced gross profit final results sirius landmark us study gross profit margin improvement cyphertmsirolimuseluting stent drugeluting coronary gross profit margin improvement stent first kind recommended fda gross profit margin gross profit approval clinical results cyphertmstent indicate sig margin improvement nificant reduction instent restenosis revascularization improvement gross profit margin past three years rates compared bare metal stents findings confirm primarily result continued improvements mix stents continued excellent performance significantly businesses successful ongoing cost control efforts reducing reblockage coronary arteries patients sellinggeneral administrative expenses coronary artery disease additionally july us consolidated selling general administrative expenses department health human services hhs made increased respec decision provide accelerated incremental reimbursement tively selling general administrative expenses percent tohospitals technology commencing april sales undernewly established diagnostic related groups drgs respectively result implementation inorder ensure access technology patients emerging issues task force eitf issue accounting rapidly possible hhs taken unprecedented step consideration given vendor customer reseller assigning new drgs prior fda approval october vendors products company reclassified million circulatory system device panel advisory panel voted million respectively fromselling favor fda approval recommended conditions general administrative expenses reductionof sales forthe companys drugeluting coronary stent company reclassified million million expense continuing work fda ongoing review respectively selling general administrative product approval expenses cost products sold also fourth quarter fdas orthopaedic advertising expenses comprised television radio rehabilitation devices panel unanimously recommended favor print media well internet advertising billion fda approval conditions independencetm billion billion ibottmmobility system ibottmmobility system unique device offers benefits individuals mobility research expenses related disabilities device used navigate difficult research activities represent significant part terrain climb stairs ramps balance standing height companys business expenditures relate develop twowheels ment new products improvement existing products december ethicon received fda clearance mar technical support products compliance governmen ket vicrylplus antibacterial suture first suture tal regulations protection consumers patients designed antibacterial agent designed reduce bacte worldwide costs research activities excluding inprocess rial colonization suture vicrylplus may help reduce research development charges follows risk complications associated surgery millions dollars worldwide sales billion medical research expense devices diagnostics segment represented total increase percent increase domestic sales interna prior year tional sales increased sales gains local currency percent sales offset negative currency impact research expense percent sales pharmaceutical worldwide sales billion medical devices segment diagnostics segment represented total increase averaging consumer consisting gains local currency medical devices diagnostics segments reduced due strength us dollar domestic respectively sales international sales increased significant research activities continued pharma sales gains local currency offset negative ceutical segment spending increasing billion currency impact representing compound annual growth rate ofapproximately forthe fiveyear period since johnson johnson pharmaceutical research development llc formerly known janssen research foundation rw johnson pharmaceutical research institute pri mary worldwide pharmaceutical research organization additional research conducted centocor alza corporation alza tibotecvirco nv collaboration james black foundation london england inprocess research development amgen retained exclusive rights second quarter company recorded warrant extraordinary remedy terminating contract process research development iprd charges mil instead found amgen could adequately compen lion aftertax million tax iprd generally sated monetary damages arbitrator awarded tax deductible us related acquisitions acquisi million damages recorded third quarter tions included tibotecvirco nv privatelyheld biopharma arbitration fourth parties ceutical company focused developing antiviral treatments since january arbitrator ruled obtech medical ag privatelyheld company markets amgen prevailing party arbitration entitling adjustable gastric band treatment morbid obesity itto award reasonable attorneys fees costs amgen fourth quarter iprd charge mil yet submitted application fees costs lion aftertax million tax iprd generally company expensed million fourth quarter tax deductible us incurred result acqui inconnection outstanding claim sition inverness medical technology supplier lifescan addition items indicated electrochemical products blood glucose monitoring follow income expense included costs related merger ing spinoff nondiabetes businesses teramed withalza million amortization expense early stage medical device company developing endovas approximately million longer required cular stentgraft systems minimally invasive treatment financial accounting standards board fasb standard abdominal aortic aneurysms peripheral occlusive disease goodwill intangible assets sfas companys iprd charges million addition items indicated aftertax million tax iprd generally income expense included favorable adjustment costs taxdeductible us related acquisition associated global manufacturing restructuring atrionix inc development stage company whose primary charge gain sale various product lines product pulmonary ablation catheter treatment earnings provision taxes income atrial fibrillation crescendo company formed alza consolidated earnings provision taxes income forthe purpose selecting developing commercializing increased human pharmaceutical products respectively excluding iprd merger charges noted interestincome expense inthe previous sections increases interest income decreased primarily due decline respectively increase us interest rates cash expended part stock due primarily volume growth improved gross profit repurchase program see average yield marginsand efficiencies spending selling marketing investments basis points aver administrative expenses age yield interest expense compared operating profit segment follows remained relatively constant significant percent changes average debt balances sales income expensenet millions dollars income expense includes gains losses related consumer thesale writedown certain equity securities pharmaceutical johnson johnson development corporation losses med devices diag disposal fixed assets currency gains losses minority segments total interests litigation settlement expense well royalty expenses income additionally income expense included allocated gain sale ortho prefest product line segments impact amgen arbitration settlement october arbitrator chicago denied earnings effort amgen inc terminate license agreement taxes income ortho biotech obtained exclusive us rights toamgendeveloped erythropoietin epo sold procriteprex indications outside kidney dialysis amgen filed suit claiming ortho biotech breached license rights improperly making sales epo amgens exclusive dialysis market decision arbi trator found sales made markets increase expenses allocated segments primarily netincome earnings per share due decline interest income discussed worldwide net earnings billion reflecting interest income expense section increase worldwide net earnings per share consumer segment operating profit increased equaled per share increase prior year reflects operating profit percent sales net earnings per share excluding impact improvement improvement due primarily iprd impact iprd merger costs leveraging ofselling promotion administrative expenses worldwide net earnings billion net earnings offset increased expenditures advertising additionally per share representing increase theconsumer segment operating profit improved respectively impact nonamortiza amortization expense longer required sfas tion per sfas increased net earnings earnings per pharmaceutical segment operating profit increased share approximately worldwide net earnings achieved reflects operating profit percent sales improvement ayear annual growth rate earnings per share pharmaceutical segment operating profit nega grew rate excluding impact accounting tively impacted cost amgen arbitration settlement change iprd worldwide net earnings million damages million legal fees achieved year annual growth rate earnings iprd related tibotecvirco nv acquisition offset per share grew rate year annual compound gain sale ortho prefest product line growth rates net earnings earnings per share impact ofsfas operating profit percent respectively excluding impact iprd sales pharmaceutical segment pharmaceutical seg merger costs worldwide net earnings achieved year annual ment operating profit also included effectof leveraging growth rate earnings per share grew rate marketing expenses pharmaceutical operating profit included expenses related merger alza worldwide net earnings billion reflecting medical devices diagnostics segment operating profit increase worldwide net earnings per share increased reflects operating profit percent equaled per share increase sales improvement nonamortization per sfas net earnings per share excluding impact accounted improvement remaining iprd merger costs iprd net favorable margin improvement prior year achieved despite adjustment costs associated global manu investment spending support cordis product line facturing restructuring charge worldwide net earnings operating profit includes iprd associated acqui billion net earnings per share repre sitions obtech medical ag inverness medical senting increase respectively technology teramed worldwide net earnings billion reflecting increase worldwide net earnings per share provision taxes income equaled per share increase worldwide effective income tax rate net earnings per share excluding impact increase effective iprd net favorable adjustment costs associated tax rate years primarily due global manufacturing restructuring charge tothe increase income subject tax us merger costs worldwide net earnings companys nondeductible iprd charge refer footnote billion net earnings per share representing financial statements additional information increase respectively cash flows liquidity cash generated operations selected borrowings pro vide major sources funds growth business including working capital capital expenditures acquisitions share repurchases dividends debt repayments cash current marketable securities billion end compared billion end cash generated operations amounted billion contractual obligations commitments less cash generated operations company longterm contractual obligations primarily billion decrease due primarily funding lease debt obligations satisfy obligations us pension plan approximately million net company intends use cash operations following current tax benefit change table summarizes companys contractual obligations timing salary increases bonuses paid employees aggregate maturities december see notes december february change enacted details results finalized order align compensation operating debt performance result change increase millions dollars leases obligations approximately million cash flows operating activities due payment bonus capital expenditures capital expenditures increased billion increased billion increase due primarily expansion manufac turing facilities support new existing products invest financial position capital resources ments support research investments information systems across business segments total assets returns total assets increased billion bil share repurchases dividends lion consolidated assets yearend february company announced stock repur medical devices diagnostics accounted chase program billion time limit pro pharmaceutical segment assets consumer gram program completed august segment assets general corporate assets million shares repurchased aggregate price bil yearend consolidated assets lion addition stock repurchase program identifiable medical devices diagnostics pharma company annual program repurchase shares use ceutical segments respectively employee stock employee incentive plans consumer segment general corporate assets respectively company increased cash dividend net intangible assets increased rep theth consecutive year cash dividends paid resented total assets yearend net property pershare compared dividends per share plant equipment increased billion per share dividends represented total assets yearend distributed follows shareholders equity per share end compared yearend decrease first quarter thedecrease primarily due billion stock repurchase second quarter program completed third quarter financing marketrisk fourth quarter company uses financial instruments manage impact total foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts january board directors declared regular protect value existing foreign currency assets liabili cash dividend per share paid march ties hedge future foreign currency product costs gains shareholders record february company losses contracts offset primarily effect expects continue practice paying regular cash dividends foreign exchange rate changes underlying transactions appreciation us dollar december market rates would increase unrealized value companys forward contracts million conversely depreciation us dollar december market rates would decrease unrealized value companys ward contracts million either scenario gain loss theforward contract would offset effect eign exchange rate changes underlying transaction company enters currency swap contracts man matters age companys exposure changes currency exchange critical accounting policies estimates rates hedging foreign currency denominated assets lia managements discussion analysis results operations bilities impact change interest rates financial condition based companys consolidated companys interest rate sensitive financial instruments would financial statements prepared accordance immaterial accounting principles generally accepted us company enter financial instruments preparation financial statements requires management trading speculative purposes company make estimates assumptions affect amounts policy entering contracts parties reported revenues expenses assets liabilities least equivalent credit rating counterparties related disclosures actual results may may differ contracts major financial institutions estimates companys significant accounting policies company significant exposure one coun described note however company believes terparty management believes risk loss remote understanding certain key accounting policies estimates total unused credit available company approximates essential achieving insight companys operat billion including billion credit commitments ing results financial condition key accounting policies billion uncommitted lines various banks worldwide estimates include revenue recognition accounting expire companys shelf registration filed income taxes legal self insurance contingencies valuation securities exchange commission enables long lived assets assumptions used determine amounts company issue billion unsecured debt securities recorded pensions employee benefit plans warrants purchase debt securities medium accounting stock options term note mtn program mtns issued revenue recognition december company billion remaining company recognizes revenue product sales shelf registration company continues one goods shipped delivered depending title companies triple credit rating risk passes customer provisions certain rebates sales total borrowings end bil incentives trade promotions coupons product returns dis lion billion respectively net cash cash counts customers provided reductions determin current marketable securities net debt billion ing sales period related sales recorded net cash cash current marketable securities net provisions largest medicaid debt billion total debt represented total capi rebateprovision based estimates derived current tal shareholders equity total debt program requirements historical experience total capital period ended december companyalso recognizes service revenue received material cash commitments summary bor copromotion certain products yearend december rowings found note revenues less total revenues company believes operations comply included product sales material respects applicable environmental laws regula tions company subsidiaries parties number income taxes proceedings brought comprehensive environmental income taxes recorded based amounts refundable response compensation liability act commonly known payable current year include results differ superfund comparable state laws relief ence us gaap accounting us tax reporting sought cost past future remediation recorded deferred tax assets liabilities company feasible predict determine outcome proceed records deferred tax assets liabilities based current tax ings opinion company proceedings would regulations rates changes tax laws rates may material adverse effect results operations cash affect deferred tax assets liabilities recorded flows financial position company future management believes changes estimates would material effect companys results operations cash flows financial position company intends continue reinvest undistributed international earnings expand international operations therefore us tax expense recorded tocover repatriation undistributed earnings december december cumulative amount undis tributed international earnings approximately billion billion respectively legal self insurance contingencies fasb issued sfas accounting costs company records accruals various contingencies associated exit disposal activities effective including legal proceedings product liability cases exit disposal activities initiated december theyarise normal course business accruals company adopt sfas first quarter based managements judgment probability expected material effect losses opinions legal counsel applicable actuari companys results operations cash flows financial position ally determined estimates additionally company records november fasb issued fasb interpretation insurance receivable amounts third party insurers based fin guarantors accounting disclosure probability ofrecovery appropriate reserves requirements guarantees including indirect guarantees receivables recorded estimated amounts may indebtedness others interpretation fasb statements collected third party insurers rescission fasb interpretation fin clarifies requirements fasb statement long lived intangible assets accounting contingencies relating guarantors company assesses changes economic conditions accounting disclosure issuance certain types strategic priorities makes assumptions regarding estimated guarantees disclosure requirements fin effec future cash flows evaluating value companys fixed tive financial statements interim annual periods assets goodwill andother noncurrent assets assump end december adopted tions estimates may change time may may company disclosure required yearend necessary forthe company record impairment charges provisions initial recognition measurement effective employee benefitplans prospective basis guarantees issued modi company sponsors various retirement pension plans fied december irrespective ofthe guarantors including defined benefit defined contribution termination yearend fin requires upon issuance guarantee indemnity plans cover employees worldwide entity must recognize liability fair value plans require assumptions discount rate expected obligation assumes guarantee companys return plan assets expected salary increases health adoption fin expected material care cost trend rates see note detail effect companys results operations cash flows rates effect change rates companys financial position results operations january fasb issued fin consolidation variable interest entitiesan interpretation arb stock options addresses consolidation variable interest entities company elected use accounting principle board fin expands criteria consideration determining opinion accounting stock issued employees whether variable interest entity consolidated apb require compensation costs related business entity requires existing unconsolidated variable stock options recorded net income options interest entities include limited special granted various stock option plans exercise purpose entities spes consolidated primary price equal market value underlying common stock beneficiaries entities effectively disperse risks grant date statement financial accounting standard among parties involved interpretation applies immediately sfas accounting stockbased compensation variable interest entities created january transition disclosure amendment fasb statement variable interest entities enterprise obtains requires pro forma disclosure net income earn interest date applies first fiscal year inter ings per share determined fair value method im period beginning june variable interest accounting stock options applied measuring entities enterprise holds variable interest compensation cost see notes information acquired february adoption fin regarding stock options expected material effect companys results new accounting standards operations cash flows financial position june fasb issued sfas accounting asset retirement obligations company adopt standard effective fiscal years beginning june expected material impact companys results operations cash flows financial posi tion august fasb issued sfas accounting impairment disposal longlived assets effective first quarter companys adoption ofsfas material effect companys results operations cash flows financial position june changing prices inflation expertise protein biology computational medicinal johnson johnson aware products used set chemistry identify novel targets rationally design small ting decade policymakers consumers molecule compounds large markets unmet medical businesses expressed concern rising cost needs scios product natrecoris first novel agent health care response concerns johnson johnson approved congestive heart failure chf longstanding policy pricing products responsibly decade natrecoris recombinant form naturally forthe period united states weighted occurring protein secreted heart part bodys average compound annual growth rate johnson johnson response chf drug several significant advantages price increases health care products prescription existing therapies chf single common cause overthecounter drugs hospital professional products hospitalization united states patients us consumer price index cpi period principal focus scios research development inflation rates even though moderate many parts program small molecule inhibitors includes several world continue effect worldwide potential new treatments pain inflammatory diseases economies consequently way companies operate including advanced p kinase inhibitor program face increasing costs company strives maintain transaction expected close second quarter profit margins cost reduction programs productivity company anticipates iprd charge improvements periodic price increases approximately million incurred connection acquisition common stock marketprices companys common stock listed new york stock cautionary factors thatmay affectfuture results exchange symbol jnj composite market price annual report contains forwardlooking statements ranges johnson johnson common stock forwardlooking statements relate strictly historical orcurrent facts anticipate results based managements plans subject uncertainty forwardlooking state ments may identified use words like plans high low high low expects anticipates estimates words first quarter ofsimilar meaning conjunction among things second quarter discussions future operations financial performance third quarter companys strategy growth product development regulatory fourth quarter approval market position expenditures yearend close forwardlooking statements based current expecta subsequentevents tions future events company guarantee february johnson johnson announced forwardlooking statement accurate although signed definitive agreement scios inc biopharmaceuti company believes reasonable expecta cal company marketed product cardiovascular dis tions assumptions investors realize underly ease research projects focused autoimmune diseases ing assumptions prove inaccurate unknown risks company acquire scios cash stock exchange uncertainties materialize actual results could vary materially terms agreement scios shareholders companys expectations projections investors receive outstanding scios share value therefore cautioned place undue reliance transaction anticipated closing date expected wardlooking statements furthermore company assumes tobe approximately billion net cash anticipated obligation update forwardlooking statements acquired based scios approximately million fully result new information future events developments diluted shares outstanding companys report year ended december boards directors johnson johnson scios filed march contain given approval transaction subject exhibit discussion various factors could cause actual toclearance hartscottrodino antitrust improve results differ expectations prior filing investors ments act transaction also subject approval reference companys report fis shareholders scios customary closing conditions cal year ended december company notes scios biopharmaceutical company developing novel factors permitted private securities litigation reform treatments cardiovascular inflammatory disease act thecompanys diseasebased technology platform integrates consolidated balance sheets johnson johnson subsidiaries december december dollars millions except share per share data note assets currentassets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes deferred taxes income note prepaid expenses receivables total currentassets marketable securities noncurrent notes property plant equipment net notes intangible assets net notes deferred taxes income note assets note total assets liabilities shareholdersequity currentliabilities loans notes payable note accounts payable accrued liabilities accrued salaries wages commissions taxes income total currentliabilities longterm debt note deferred tax liability note employee related obligations note liabilities shareholdersequity preferred stockwithout par value authorized unissued shares common stockpar value per share note authorized shares issued shares note receivable employee stock ownership plan note accumulated comprehensive income note retained earnings less common stock held treasury cost note total shareholdersequity total liabilities shareholdersequity see notes consolidated financial statements consolidated statements earnings johnson johnson subsidiaries dollars millions except per share figures note sales customers cost products sold gross profit selling marketing administrative expenses research expense purchased inprocess research development note interest income interest expense net portion capitalized note income expense net earnings provision taxes income provision taxes income note netearnings basic netearnings per share notes diluted netearnings per share notes see notes consolidated financial statements consolidated statements equity johnson johnson subsidiaries note receivable accumulated common employee stock treasury comprehensive retained stock ownership comprehensive issued stock dollars millions note total income earnings plan esop income amount amount balancejanuary net earnings cash dividends paid employee stock compensation stock option plans conversion subordinated debentures repurchase common stock business combinations comprehensive income net tax currency translation adjustment unrealized gainslosses securities pension liability adjustment reclassification adjustment total comprehensive income note receivable esop balancedecember net earnings cash dividends paid employee stock compensation stock option plans conversion subordinated debentures repurchase common stock business combinations comprehensive income net tax currency translation adjustment unrealized gainslosses securities gainslosses derivatives hedges reclassification adjustment total comprehensive income note receivable esop balancedecember net earnings cash dividends paid employee stock compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized gainslosses securities pension liability adjustment gainslosses derivatives hedges reclassification adjustment total comprehensive income note receivable esop balancedecember see notes consolidated financial statements consolidated statements cash flows johnson johnson subsidiaries dollars millions note cash flows operating activities net earnings adjustments reconcile net earnings cash flows depreciation amortization property intangibles purchased inprocess research development deferred tax provision accounts receivable reserves changes assets liabilities net effects acquisition businesses increase accounts receivable increase decrease inventories increase accounts payable accrued liabilities increase decrease current noncurrent assets increase current noncurrent liabilities netcash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assets acquisition businesses net cash acquired note purchases investments sales investments netcash used investing activities cash flows financing activities dividends shareholders repurchase common stock proceeds shortterm debt retirement shortterm debt proceeds longterm debt retirement longterm debt proceeds exercise stock options netcash used financing activities effect exchange rate changes cash cash equivalents decrease increase cash cash equivalents cash cash equivalents beginning year note cash cash equivalentsend year note supplemental cash flow data cash paid year interest income taxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds conversion debt acquisition businesses fair value assets acquired fair value liabilities assumed treasury stock issued fair value net cash paid acquisitions see notes consolidated financial statements notes consolidated financial statements summary significantaccounting principles variable interest entities enterprise obtains interest date applies first fiscal year principles consolidation interim period beginning june variable interest financial statements include accounts johnson entities enterprise holds variable interest johnson subsidiaries intercompany accounts acquired february adoption fin transactions eliminated expected material effect companys results new accounting pronouncements operations cash flows financial position june financial accounting standards board cash equivalents fasb issued statement financial accounting standard company considers securities maturities three sfas accounting asset retirement obligations months less purchased cash equivalents company adopt standard effective investments fiscal years beginning june shortterm marketable securities carried cost expected material impact companys results approximates fair value longterm debt securities operations cash flows financial position august company ability intent hold maturity thefasb issued sfas accounting impairment carried amortized cost also approximates fair value disposal longlived assets effective investments classified availableforsale carried first quarter companys adoption sfas estimated fair value unrealized gains losses recorded material effect companys results component accumulated comprehensive income operations cash flows financial position june management determines appropriate classification fasb issued sfas accounting costs associated investment debt equity securities time purchase exit disposal activities effective exit reevaluates determination balance sheet disposal activities initiated december date company periodically reviews investments non companys adoption sfas first quarter marketable equity securities impairment adjusts expected material effect com investments fair value decline market value panys results ofoperations cash flows financial position deemed temporary november fasb issued fasb interpretation fin guarantors accounting disclosure propertyplantand equipmentand depreciation requirements guarantees including indirect guarantees property plant equipment stated cost indebtedness others interpretation fasb statements companyutilizes straightline method depreciation rescission fasb interpretation overthe estimated useful lives assets fin clarifies requirements fasb statement building building equipment years accounting contingencies relating guarantors land leasehold improvements years accounting disclosure issuance certain types machinery equipment years ofguarantees disclosure requirements fin effec tive financial statements interim annual periods company capitalizes certain computer software end december disclosure provisions development costs incurred connection developing implemented disclosures required year orobtaining computer software internal use capitalized end provisions initial recognition measure software costs amortized estimated useful lives ment effective prospective basis guarantees ofthe software generally ranges years issued modified december irrespective company reviews longlived assets assess recoverabil guarantors yearend fin requires upon issuance ity using undiscounted cash flows necessary charges guarantee entity must recognize aliability fair value impairments longlived assets recorded amount obligation assumes guarantee com bywhich present value future cash flows less panys adoption fin andis expected carrying value assets material effect companys results operations revenue recognition cash flows financial position company recognizes revenue product sales january fasb issued fin consolidation goods shipped delivered depending title variable interest entitiesan interpretation arb riskpasses customer provisions certain rebates sales addresses consolidation variable interest entities fin incentives trade promotions product returns discounts expands criteria consideration determining customers provided reductions determining sales whether variable interest entity consolidated inthe period related sales recorded business entity requires existing unconsolidated variable interest entities include limited special sales incentives trade promotional allowances purpose entities spes consolidated primary company adopted emerging issues task force eitf beneficiaries entities effectively disperse risks issue accounting consideration given vendor among parties involved interpretation applies immediately customer reseller vendors products effective decem variable interest entities created january ber prior periods restated reclassify sales incentives trade promotional allowances selling values derivatives recognized earnings thereby general administrative expenses either reduction offsetting current earnings effect related foreign sales cost sales assuch sales reduced mil currency assets liabilities lion million respectively cost designation cash flow hedge made date products sold increased million million ofentering derivative contract inception deriva respectively tives expected highly effective changes fair value derivative designated cash flow hedge shipping handling highly effective recorded accumulated shipping handling costs incurred million comprehensive income underlying transaction affects million million respectively earnings reclassified earnings included selling marketing administrative account hedged transaction fair value forward expense amount revenue received shipping exchange contract represents present value change handling immaterial periods presented forward exchange rates times notional amount inventories derivative fair value currency swap contract deter inventories stated lower cost market mined discounting present future cash flows determined firstin firstout method currencies exchanged interest ratesprevailing market periods currency exchanges due intangible assets expressing result us dollars atthe current spot accordance sfas amortization foreign currency exchange rate recorded goodwill andor intangible assets deemed ongoing basis company assesses whether indefinite lives acquisitions completed june derivative continues highly effective offsetting changes effective beginning fiscal year accor cash flows hedged items derivative dance sfas company discontinued amor isno longer expected highly effective hedge accounting tization relating existing goodwill indefinite lived discontinued hedge ineffectiveness included intangible assets effect nonamortization good current period earnings intangible assets approximately mil company documents relationships hedged lion tax intangible assets finite items derivatives overall risk management strategy useful lives continue beamortized useful lives includes reasons undertaking hedge transactions sfas requires goodwill nonamortizable entering derivatives objectives strategy intangible assets assessed annually impairment minimize foreign currency exposures impact required initial assessment completed june companys financial performance protect companys impairment determined initial impairment cash flow adverse movements foreign exchange assessment updated fourth quarter rates ensure appropriateness financial instruments impairment determined future impairment tests manage enterprise risk associated finan performed fourth quarter annually cialinstitutions financial instruments productliability effective january company adopted sfas accruals product liability claims recorded accounting derivative instruments hedging activi undiscounted basis probable liability ties amended sfas accounting certain incurred amount liability reason derivative instruments certain hedging activities ably estimated based existing information accruals amendment fasb statement collectively referred adjusted periodically additional information becomes sfas sfas requires derivative available receivables insurance recoveries related prod instruments recorded balance sheet fair value uct liability related claims recorded undiscounted changes fair value derivatives recorded time value money basis probable period current earnings comprehensive income recovery realized depending whether derivative designated part hedge transaction depending type research development hedge transaction research development expenses expensed company uses forward exchange contracts manage incurred upfront milestone payments made third exposure variability cash flows primarily related parties connection research development col foreign exchange rate changes future intercompany laborations expensed incurred point product third party purchases raw materials denomi regulatory approval payments made third parties subse nated foreign currency company also uses currency quent regulatory approval capitalized amortized swaps manage currency risk primarily related borrow remaining useful life related product amounts ings types derivatives designated cash capitalized suchpayments included intangi flow hedges additionally company uses forward exchange bles net accumulated amortization contracts offset exposure certain foreign currency advertising assets liabilities forward exchange contracts costs associated advertising expensed year designated hedges therefore changes fair incurred advertising expenses worldwide comprised television radio print media well internet us requires management make estimates assump advertising billion billion tions affect amounts reported actual results may billion may differ estimates income taxes annual closing date company intends continue reinvest undistributed company follows concept fiscal year ends international earnings expand international operations onthe sunday nearest end month december therefore us tax expense recorded cover normally fiscal year consists weeks every five repatriation ofsuch undistributed earnings december six years case fiscal year consists december cumulative amount weeks undistributed international earnings approximately reclassification billion billion respectively certain prior year amounts reclassified conform deferred income taxes recognized tax consequences current year presentation temporary differences applying enacted statutory tax rates applicable future years differences financial stock split reporting tax basis existing assets liabilities april board directors declared stock split shareholders record close business netearnings per share may issued one additional share johnson basic earnings per share computed dividing net income johnson common stock june share held available common shareholders weighted average record date shares pershare data number common shares outstanding period diluted periods presented financial statements earnings per share reflects potential dilution could adjusted reflect stock split occur securities contracts issue common stock exercised converted common stock inventories stock options end inventories comprised december company stockbased dollars millions employee compensation plans described note raw materials supplies company accounts plans recognition goods process measurement principles accounting principle board finished goods opinion accounting stock issued employees andits related interpretations compensation costs recorded net income stock options options granted plans exercise price equal market propertyplantand equipment value underlying common stock date grant end property plant equipment required sfas accounting stockbased cost accumulated depreciation compensationtransition disclosurean amendment dollars millions offasb statement following table shows land land improvements estimated effect net income earnings per share buildings building equipment company applied fair value recognition provision machinery equipment sfas accounting stockbased compensation construction progress tostockbased employee compensation dollars millions less accumulated depreciation except per share data net income reported company capitalizes interest expense part cost less ofconstruction facilities equipment interest expense compensation capitalized million million expense million respectively pro forma depreciation expense including amortization capital ized interest billion billion earnings per share billion respectively basicas reported upon retirement disposal fixed assets cost pro forma andrelated amount accumulated depreciation amortization dilutedas reported eliminated asset accumulated depreciation pro forma accounts respectively difference net asset value proceeds adjusted toearnings determined fair value based method awards net tax risks uncertainties rental expense lease commitments preparation consolidated financial statements rentals space vehicles manufacturing equipment office conformity accounting principles generally accepted data processing equipment operating leases amounted approximately million million company access substantial sources funds million numerous banks worldwide total unused credit available approximate minimum rental payments required company approximates billion including billion operating leases initial remaining noncancelable credit commitments billion uncommitted lines lease terms excess one year december various banks worldwide expire interest charged borrowings credit line agreements dollars millions total based either bids provided banks prime rate london interbank offered rates libor plus applicable mar gins commitment fees agreements material commitments capital leases significant companys shelf registration filed securities exchange commission enables company issue employee related obligations billion unsecured debt securities warrants purchase end employee related obligations debt securities medium term note mtn program mtns issued december company dollars millions billion remaining shelf registration pension benefits long term debt includes two convertible subordinated post retirement benefits debentures issued alza prior merger post employment benefits johnson johnson deferred compensation july alza completed private offering zero coupon convertible subordinated debentures current benefits payable issued price per principal amount maturity december outstanding deben employee related obligations tures total principal amount maturity billion yield maturity per annum computed prepaid employee related obligations million semiannual bond equivalent basis periodic inter included assets consolidated balance sheet est payments terms debentures holders entitled convert debentures approximately borrowings million shares johnson johnson stock price components longterm debt follows per share approximately shares eff eff issued december due voluntary conversions dollars millions rate rate note holders option holder debentures zero coupon may repurchased company july convertible purchase price equal issue price plus accreted subordinateddebentures original issue discount purchase date company due option may elect deliver either johnson johnson com zero coupon mon stock cash combination stock cash convertible event repurchase debentures company subordinateddebentures option may also redeem debentures due july issue price plus accreted original issue debentures discount december december due fair value based quoted market value debentures notes due million million respectively debentures alza issued zero coupon convertible due subordinated debentures price per prin notes due cipal amount maturity december outstand eurodollar notes ing debentures total principal amount maturity due million yield maturity per annum notes due computed semiannual bond equivalent basis notes due periodic interest payments terms deben industrial revenue bonds tures note holders entitled convert debentures principally approximately million shares johnson johnson international stock price per share approximately mil lion shares johnson johnson stock issued less current portion december due voluntary conversions note hold ers option holder debentures may purchased company july july weighted average effective rate purchase price equal issue price plus accreted represents us dollar notes due issued japanese original issue discount purchase date december subsidiary converted fixed rate yen note via currency swap december fair value based quoted market value debentures million weighted average amortization periods patents million respectively trademarks intangible assets years shortterm borrowings current portion longterm years respectively amortization expense amortizable debtamounted billion end intangible assets forthe fiscal year ended december borrowings comprised billion commercial paper millionpretax estimated amortization million local borrowings principally interna expense fivesucceeding years approximates tional subsidiaries million pretax per yearrespectively aggregate maturities longterm obligations commencing income taxes provision taxes income consists dollars millions dollars millions currently payable us taxes intangible assets international taxes end gross net amounts intangible assets deferred dollars millions us taxes goodwillgross international taxes less accumulated amortization goodwillnet trademarks nonamortizablegross comparison income tax expense federal statutory less accumulated amortization rate companys effective trademarks nonamortizablenet tax rate follows patents trademarksgross dollars millions less accumulated amortization us international patents trademarksnet earnings taxes intangiblesgross income less accumulated amortization statutory taxes intangiblesnet tax rates statutory total intangible assetsgross puerto rico less accumulated amortization ireland operations total intangible assetsnet research tax credits domestic state local goodwill december allocated segments international business follows subsidiaries med dev excluding ireland dollars millions consumer pharm diag total iprd goodwill net accumulated effective tax rate amortization december company subsidiaries operating reclassification puerto rico tax incentive grant expiring intangibles net addition company subsidiaries manufacturing ireland accumulated incentive tax rate effective year amortization acquisitions translation goodwill december temporary differences carry forwards common stockstock option plans stock asfollows compensation agreements december company stockbased com deferred tax deferred tax pensation plans stock option plan com dollars millions asset liability asset liability pany may grant options employees employee related issued shares companys common stock plus num obligations ber shares available previous year depreciation issued well shares issued plan expired nondeductible orterminated without exercised shares outstanding intangibles contracts companys international rd employee stock option plans nonemployee direc capitalized tax tors plan mitek cordis biosense gynecare centocor reserves liabilities innovasive devices alzaand inverness stock option plans income reported stock options generally expire years date tax purposes granted vest service periods range one miscellaneous six years options granted current market price international date grant shares available stock capitalized intangible option plan future grants based issued miscellaneous us shares year million shares could granted total deferred year years addition income taxes available shares described shares avail able future grants plan million difference net deferred tax income per atthe end thebalance sheet net deferred tax included summary status companys stock option taxes income balance sheet plans december december december changes years ending international currency translation dates ispresentedbelow weighted translation subsidiaries operating nonus dollar options average currencies company determined local curren shares thousands outstanding exercise price cies international subsidiaries functional curren balance january cies except highly inflationary economies options granted defined compound cumulative rates options exercised inflation past three years options canceledforfeited consolidating international subsidiaries balance sheet cur balance december rency effects recorded component accumulated options granted comprehensive income equity account includes results options exercised translating balance sheet assets liabilities current options canceledforfeited exchange rates except located highly inflationary balance december economies reflected operating results options granted analysis changes foreign options exercised currency translation adjustments included note options canceledforfeited net currency transaction translation gains lossesincluded expense aftertax losses balance december million million million includes options issued replace inverness options outstanding respectively granted prior acquisition year ended december change accumulated comprehensive income inthe timing granting stock compensation options components comprehensive incomeloss consist employees december february following change enacted results finalized order total align compensation performance timing unrealized gains accumulated foreign gains pension losses grants followed fiscal currency losses liability derivatives comprehensive dollars millions translation securities adjustments hedges incomeloss average fair value options granted jan fair value changes estimated using blackscholes option pricing model based dec weighted average assumptions changes transition riskfree rate adjustment volatility net change due expected life yrs yrs yrs hedging dividend yield transactions net amount following table summarizes stock options outstanding reclassed exercisable december net earnings shares thousands outstanding exercisable net average average exercise average exercise exercise changes price range options lifea price options price dec changes net change due hedging transactions net amount reclassed net earnings net aaverage contractual life remaining years changes dec stock options exercisable december december options average exercise total comprehensive income includes price options average exercise price reclassification adjustment gains million realized respectively sale equity securities associated taxexpense million total comprehensive income included reclassification adjustment gains million real segments business geographic areas ized sale equity securities associated tax see information segments business expense million total comprehensive geographic areas income included reclassification adjustment gains mil lion associated tax expenseof million tax effect unrealized gainslosses equity securities benefit million expense million expense million tax effect gainslosses derivatives hedges benefit million andan expense million see note additional information relating derivatives hedging currency translation adjustments currently adjusted income taxes relate permanent investments nonus subsidiaries retirementand pension plans funds sufficient provide accrued benefits international subsidiaries plans funds deposited company sponsors various retirement pension trustees annuities purchased group contracts plansincluding defined benefit defined contribution reserves provided termination indemnity plans cover employees certain countries united states funding worldwide company also provides postretirement pension plans common practice funding provides benefits primarily health care domestic retired economic benefit consequently company several pension employees dependents plans funded international employees covered government company fund retiree health care benefits sponsored programs cost companyis advance right modify plans thefuture significant net periodic benefit costs companys defined benefit retirement plan benefits primarily based retirement plans benefit plans employees compensation last three five years include following components retirement number years service com panys objective funding domestic plans accumulate retirement plans benefit plans dollars millions service cost interest cost expected return plan assets amortization prior service cost amortization net transition asset recognized actuarial gains curtailments settlements net periodic benefit cost net periodic income cost attributable domestic retire ment plans million million million following tables provide weightedaverage assump tions used develop net periodic benefit cost actuar ial present value projected benefit obligations retirement plans benefit plans domestic benefitplans weighted average discount rate expected longterm rate return plan assets rate increase compensation levels international benefitplans weighted average discount rate expected longterm rate return plan assets rate increase compensation levels health care cost trends united states projected plan assets consist primarily listed common stocks us annual rates individuals grading nonus equities fixed income investments fair year beyond effect change value johnson johnson common stock plan assets assumed cost trends accumulated postretirement million december benefit obligation atthe end would million increase million decrease effect service interest costcomponents net periodic postretirement benefit cost would million increase million decrease following tables set forth change benefit obliga tions change plan assets yearend companys defined benefit retirement plans benefit plans dollars millions retirement plans benefit plans change benefitobligation benefit obligationbeginning year service cost interest cost plan participant contributions amendments actuarial loss divestitures acquisitions curtailments settlements total benefits paid effect exchange rates benefit obligationend year change plan assets plan assets fair valuebeginning year actual return plan assets company contributions plan participant contributions divestitures benefits paid plan assets effect exchange rates plan assets fair valueend year amounts recognized companys balance sheetconsistof following retirement plans benefit plans dollars millions plan assets less projected benefit obligation unrecognized actuarial lossesgains unrecognized prior service cost unrecognized net transition asset total recognized consolidated balance sheet book reserves prepaid benefits intangible assets accumulated comprehensive income total recognized consolidated balance sheet minimum pension liability adjustment required minimum pension liability adjustments actuarial present value accumulated benefits abo exceeds million million respectively relate primarily fair value plan assets accrued pension liabilities plans outside us plans accumulated benefitobligations excess plan assets consistof following retirement plans benefit plans dollars millions accumulated benefit obligation projected benefit obligation plan assets fair value marketable securities december december net unrealized unrealized estimated net unrealized unrealized estimated dollars millions cost gains losses fair value cost gains losses fair value money market funds commercial paper time deposits government securities obligations asset backed securities bank notes corporate debt securities total current marketable securities government securities asset backed securities bank notes corporate debt securities investments held trust total noncurrent marketable securities current marketable securities include billion billion classified cash equivalents balance sheet december december respectively financial instruments concentration creditrisk company invests excess cash deposits effective january company adopted sfas withmajor banks throughout world high quality requiring derivative instruments recorded money market instruments refer note additional thebalance sheet fair value information company policy making investments december balance deferred net losses onlywith commercial institutions least derivatives included accumulated comprehensive orequivalent credit rating investments generally income million aftertax additional information mature within six months company incurred see note amount company expects related losses million reclassified earnings next months result transactions expected occur period amount ultimately realized savings plan earnings differ foreign exchange rates change realized company voluntary k savings plans designed gains losses ultimately determined byactual exchange enhance existing retirement programs covering eligible rates maturity derivative transactions third employees company matches percentage parties cause amount accumulated compre employees contributions consistent provisions hensive income affect net earnings maximum length plan heshe eligible oftime company hedging months us salaried plan onethird company match year ended december net impact paid company stock employee stock ownership hedges ineffectiveness companys financial statements plan esop establish esop company insignificant year ended december loaned million esop trust purchase shares company recorded net gain million tax company stock open market exchange com income expense net category consolidated pany received note balance recorded statement earnings representing impact discontinu reduction shareholders equity ance cash flow hedges probable origi total contributions plans million nally forecasted transactions occur end million million originally specified time period refer note disclosures movements accumulated comprehensive income mergers acquisitions accounted purchase method accordingly results operations included accompanying certain businesses acquired million cash consolidated financial statements respective dates liabilities assumed million assumed acquisition acquisitions accounted purchase method acquisitions included inverness medical technol accordingly results operations included ogy supplier lifescans electrochemical products accompanying consolidated financial statements blood glucose monitoring following spinoff non respective dates acquisition diabetes businesses heartport company develops acquisitions included tibotecvirco nv manufactures products less invasive open chest mini privatelyheld biopharmaceutical company focused devel mally invasive heart operations including stopped heart oping antiviral treatments micro typing systems inc beating heart procedures teramed inc earlystage manufacturer reagents supplier distributed instru medical device company developing endovascular ments known idmicro typing systemtmand obtech stentgraft systems minimally invasive treatment medical ag privatelyheld company markets abdominal aortic aneurysms peripheral occlusive disease adjustable gastric band treatment morbid obesity babycenter llc internet content commerce com excess purchase price estimated fair value pany devoted supporting community expectant tangible assets acquired entities amounted new mothers viactivproduct line chewable cal million hasbeen allocated identifiable intangibles cium supplement mead johnson nutritionals divi goodwill addition approximately million sion bristolmyers squibb identified value inprocess research development inverness medical technology acquired enhance iprd associated tibotecvirco nv obtech control primary supplier lifescan blood glucose mon medical ag acquisitions itoring products allow achievement opera iprd charge related tibotecvirco nv tional synergies acquisition also provides key technology million associated two early stage hiv compounds development future products value iprd calculated assistance approximately million identified value third party appraiser using cash flow projections discounted iprd associated inverness medical technology risk inherent projects using probability suc teramed inc acquisitions iprd charge primar cess factors ranging discount rate ily related inverness projects minimally invasive testing iprd charge related obtech medical ag continuous monitoring insulin delivery value million associated development current iprd calculated assistance third party swedish adjustable gastric band sagb use united appraiser using cash flow projections discounted risk states well development next generation technology inherent projects using probability success factors platform value iprd calculated ranging discount rate used assistance third party appraiser using cash flow projec certain businesses acquired million tions discounted risk inherent projects using acquisitions accounted purchase probability success factor discount rate method accordingly results operations pro forma information provided since impact included accompanying consolidated financial state acquisitions material effect com ments respective dates acquisitions panys results operations cash flows financial position acquisitions included crescendo company june johnson johnson alza cor formed alza purpose selecting developing poration alza completed merger two commercializing human pharmaceutical products innovasive companies transaction accounted pooling devices company manufactures sells devices ofinterests alza approximately million shares sports medicine surgery soft tissue injuries atrionix inc standing million fully diluted basis thatwere adevelopment stage company whose primary product exchanged approximately million shares ofjohnson pulmonary ablation catheter treatment atrial fibril johnson common stock diluted basis whenadjusted lation medtrex company develops manufactures stock options convertible debt number johnson electrosurgical generators disposable products johnson shares issued total approximately million st josephaspirin business iprd writeoff associated holders alza common stock received share atrionix inc alzas crescendo acquisition johnson johnson common stock valued per share million iprd charge primarily related atrionix alza researchbased pharmaceutical company project design catheter system used leading drug delivery technologies company applies procedure blocks electrical impulses originating pul delivery technologies develop pharmaceutical products monary veins cause atrial fibrillation value withenhanced therapeutic value johnson johnson iprd calculated assistance third party affiliate portfolios many worlds leading appraiser using cash flow projection discounted risk pharmaceutical companies inherent project discount rate used certain businesses acquired billion divestitures material billion cash liabilities assumed effecton companys results operations cash flows million shares companys common stock issued financial position treasury valued billion acquisitions legal proceedings respect various propulsidactions janssen company dispute claims company involved numerous product liability cases lawsuits vigorously defending except united states many concern adverse reactions judgment settlement appropriate janssen drugs medical devices damages claimed substan company believe adequate selfinsurance tial company confident adequacy reserves commercially available excess insurance warnings instructions use accompany prod respect cases communications company ucts feasible predict ultimate outcome litiga excess insurance carriers raised certain defenses tion however company believes liability results liability policies however opinion com cases substantially covered reserves pany defenses pro forma lack substance established selfinsurance program commer carriers honor obligations policies cially available excess liability insurance companys ortho biotech subsidiary party one group cases company concerns arbitration proceeding filed amgen ortho janssen pharmaceutica product propulsid biotechs licensor us nondialysis rights procrit drawn general sale restricted limited use amgen sought terminate ortho biotechs us license wake publicity events numerous lawsuits rights collect substantial damages based alleged delib filed janssen wholly owned erate procritsales ortho biotech early subsidiary company company regarding amgens reserved dialysis market october propulsidin state federal courts across country thearbitrator issued decision rejecting amgens request approximately cases currently pending toterminate license finding material breach including theclaims approximately plaintiffs license however arbitrator found conduct ortho recently filed mississippi avoid application tort biotech early subsequently halted reform legislation effective january cases byortho biotech amounted nonmaterial breach likely filed mississippi yet served license awarded amgen million damages active cases individuals alleged died thecompany expensed third quarter amgen use propulsid actions seek substantial compen hadsought billion damages january satory punitive damages accuse janssen arbitrator ruled amgen prevailing party company inadequately testing warning arbitration entitling award reasonable attorneys fees drugs side effects promoting offlabel use costs amgen yet submitted application forfees promotion addition janssen company entered costs company expensed million fourth agreements various plaintiffs counsel halting run quarter connection outstanding claim ning statutes limitations respect potential patent infringement actions tried delaware federal claims significant number individuals attor court late cordis corporation subsidiary johnson neys evaluate whether sue janssen company johnson obtained verdicts infringement patent valid behalf ity damage awards boston scientific corporation september first plaintiffs rankin case medtronic ave inc based number cordis coro comprises claims propulsidplaintiffs went nary stent patents december jury dam trial state court claiborne county mississippi jury age action boston scientific returned verdict returned compensatory damage verdicts plaintiff million december jury medtronic amount million total million trial ave action returned verdict million sums rep judge thereafter dismissed claims punitive damages resent lost profit reasonable royalty damages compen march trial judge reduced verdicts total sate cordis infringement include pre post million denied motions janssen com judgment interest february hearing held pany new trial janssen company believe claims boston scientific medtronic ave patents verdicts even reduced insupportable issue unenforceable owing alleged inequitable con appealed view janssen company proof duct patent office march may trial demonstrated none plaintiffs injured district judge issued post trial rulings confirmed propulsidand basis liability existed validity enforceability main cordis stent patent april state court judge new jersey denied claims found certain cordis patents unenforceable plaintiffs motion certify national class propulsid district judge granted boston scientific new users purposes medical monitoring refund trialon liability damages vacated verdict costs purchasing propulsid effort appeal ruling medtronic ave legal grounds appeals federal circuit denied june federal judge presiding court appeals underway propulsidmultidistrict litigation new orleans products various johnson johnson operating com louisiana similarly denied plaintiffs motion certify panies subject various patent lawsuits could national class propulsidusers plaintiffs multi potentially affect ability operating companies sell district litigation said preserving right products require payment past damages future appeal ruling complaints filed janssen royalties respect patent challenges generic phar company include class action allegations could maceutical firms result introduction generic versions basis future attempts classes certified products question ensuing loss market share earnings per share following patent lawsuits concern important products following reconciliation basic net earnings per share johnson johnson operating companiesmedtronic diluted net earnings per share years ended decem ave v cordis corporation action filed april ber december december infederal court texas asserts certain patents owned shares millions medtronicave cordis bxvelocitytmstent basic earnings per share isalso stent structure used cyphertmdrug eluting average shares product trial date set action ortho phar outstandingbasic maceutical v barr laboratories inc pending federal court potential shares new jersey action filed june involves barrs exercisable effort invalidate orthos patents covering ortho tri stock option plans cyclenoral contraceptive product trial yet less shares repurchased scheduled case orthomcneil daiichi inc v mylan treasury stock method laboratories andorthomcneil daiichi inc v teva phar convertible debt shares maceutical matters first filed febru ary federal court west virginia second adjusted average shares june federal court new jersey concern efforts outstandingdiluted mylan teva invalidate establish noninfringement diluted earnings per share patent covering levaquinlevofloxacin tablets patent diluted earnings per share calculation includes dilution owned daiichi exclusively licensed orthomcneil effect convertible debt decrease interest expense mylan case trial hasbeen set late trial date million million million tax years set teva matter janssen alza v mylan labo respectively ratories action filed federal district court vermont diluted earnings per share excludes million shares february concerns mylans effort invalidate assert options years million noninfringement ofalzas patent covering duragesic shares ofoptions year exercise price product trial likely spring respect ofthese options greater average market matters thejohnson johnson operating com valueresulting antidilutive effect diluted earnings pany involved vigorously defending validity asserting per share infringement itsown licensors patents product accused infringing patents held others defend ing claims capital treasury stock company also involved number patent changes treasury stock trademark lawsuits incidental business treasury stock ultimate legal financial liability company nd uo mlla bers r oin f sm hi rio en ne x tc op ut sands shares amount respect claims lawsuits proceedings referred balance january estimated certainty however employee compensation stock opinion management based examination option plans matters experience date discussions counsel conversion subordinated debentures ultimate outcome legal proceedings net liabili repurchase common stock ties already accrued companys consolidated balance business combinations sheet expected material adverse effect companys consolidated financial position although reso balance december lution reporting period one matters employee compensation stock could significant impact companys results option plans operations period conversion subordinated debentures repurchase common stock business combinations balance december employee compensation stock option plans conversion subordinated debentures repurchase common stock balance december shares common stock authorized issued shares end selected quarterly financial data unaudited selected unaudited quarterly financial data years summarized first second third fourth first second third fourth dollars millions except per share amounts quarter quarter quarter quarter quarter quarter quarter quarter segment sales customers consumer pharmaceutical med devices diagnostics total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share second quarter includes tax charge million relating inprocess research development iprd costs third quarter includes tax charge million relating amgen arbitration settlement fourth quarter includes tax charge million relating amgen legal fees second quarter includes tax charge million relating alza merger costs third quarter includes tax charge million relating alza merger costs fourth quarter includes tax charge million relating iprd costs fourth quarter also includes tax charge million relating lifescan class action settlement subsequentevent scios biopharmaceutical company developing novel treatments cardiovascular inflammatory disease february johnson johnson announced thecompanys diseasebased technology platform integrates signed definitive agreement scios inc biopharmaceu expertise protein biology computational medicinal tical company marketed product cardiovascular dis chemistry identify novel targets rationally design small ease research projects focused autoimmune diseases molecule compounds large markets unmet medical company acquire scios cash stock exchange needs scios product natrecoris recombinant form terms agreement scios shareholders anaturally occurring protein secreted heart part receive outstanding scios share value thebodys response congestive heart failure chf drug transaction anticipated closing date expected several significant advantages existing therapies tobe approximately billion net cash anticipated chf single common cause hospitalization acquired based scios approximately million fully united states patients diluted shares outstanding principal focus scios research development boards directors johnson johnson scios program small molecule inhibitors includes several havegiven approval transaction subject potential new treatments pain inflammatory diseases toclearance hartscottrodino antitrust improve including advanced p kinase inhibitor program ments act transaction also subject approval transaction expected close second quarter shareholders scios customary closing conditions independent auditors report shareholders board directors johnson johnson opinion accompanying consolidated balance sheets related consolidated statements earnings consoli dated statements equity consolidated statements cash flows present fairly material respects financial position johnson johnson subsidiaries december december results operations cash flows three years inthe period ended december conformity accounting principles generally accepted united states america financial statements responsibility companys management responsibility express opinion financial statements based audits conducted audits statements accordance auditing standards generally accepted united states america require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant esti mates made management evaluating overall finan cial statement presentation believe audits provide reasonable basis opinion discussed notes financial statements company adopted statement financial accounting standards goodwill intangible assets effective december new york new york january except note date isfebruary segments business johnson johnson subsidiaries sales customers dollars millions consumerdomestic international total pharmaceuticaldomestic international total medical devices diagnosticsdomestic international total worldwide total operating profit identifiable assets dollars millions consumer pharmaceutical medical devices diagnostics segments total expenses allocated segments general corporate worldwide total additions property depreciation plant equipment amortization dollars millions consumer pharmaceutical medical devices diagnostics segments total general corporate worldwide total geographic areas sales customers longlived assets dollars millions united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total see managements discussion analysis pages description segments company business export sales intersegment sales significant sales three distributors accounted total revenues saleswere concentrated pharmaceutical segment sales procriteprexaccounted total company revenues respectively amounts allocated segments include interest incomeexpense minority interest general corporate income expense general corporate includes cash marketable securities includes million inprocess research development iprd million million amgen costs pharmaceutical segment million iprd medical devices diagnostics segment includes million alza merger costs pharmaceutical segment million iprd million ofclass action settlement medical devices diagnostics segment includes restructuring gains million consumer segment million million iprd charges net restructuring gains pharmaceutical medical devices diagnostics segments respectively summary operations statistical data johnson johnson subsidiaries dollars millions except per share figures sales customersdomestic sales customersinternational total sales cost products sold selling marketing administrative expenses research expense purchased inprocess research development interest income interest expense net portion capitalized income expense net earnings provision taxes income provision taxes income earnings cumulative effect accounting changes cumulative effect accounting changes net tax netearnings percent sales customers diluted net earnings per share common stock percent return average shareholders equity percentincrease decrease previous year sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maintenance repairs total tax expense supplementary balance sheetdata property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders equity per share market price per share yearend close average shares outstanding millionsbasic diluted employees thousands adjusted reflect twoforone stock split excluding cumulative effect accounting changes million earnings percent sales customers accounting changes earnings per share accounting change earnings percent return average shareholders equity accounting changes diluted net earnings per share percent increase prior year accounting changes diluted net earnings per share increase prior year excluding inprocess research development iprd merger restructuring costs diluted net earnings per share increase prior year diluted net earnings per share increase prior year diluted net earnings per share increase prior year diluted net earnings per share increase prior year diluted net earnings per share increase prior year cost products sold includes million inventory writeoffs restructuring percent return average shareholders equity earnings percent sales customers diluted net earnings per share increase prior year periods adjusted include effects alza merger net interest income also included cost materials services category includes taxes income payroll property business taxes principal global affiliates advanced sterilization products division ethicon inc develops manufactures markets range sterilization systems based patented low temperature hydrogen peroxide gas plasma process well sterilizingdisinfecting solutions sterradsterilization system safe fast environmentally friendly effective used broad range medical products health care facilities cidexopa solution fast effective method disinfect wide wwwsterradcom range instruments endoscopes alzacorporation pioneered continues lead development drug deliverybased pharmaceuticals johnson johnson companies enhance health care millions patients worldwide alzaalso partners leading pharmaceutical biotechnology companies develop products address unmet patient needs precisely controlling wwwalzacom targeting timing dosing therapeutic compounds babycenter llc leading online pregnancy parenting resource reaching millions new moms month web sites babycentercom parentcentercom compa ny provides awardwinning health child development parenting information customized womans stage pregnancy childs age babycenter also offers online baby store wwwbabycentercom thriving online community centocor inc leading fully integrated biopharmaceutical biotechnology company special izing development commercialization therapeutic products meet critical human health care needs world leader monoclonal antibody technology manufacturing centocor manufactures products including remicadeinfliximab treatment rheumatoid arthri tis crohns disease reoproabciximab use percutaneous coronary intervention wwwcentocorcom retavasereteplase clot buster administered heart attack cordis corporation global leader developing marketing devices circulatory disease management including stents balloons catheters used treating cardiovascular disease related conditions products marketed clinical application four main divisions cordis cardiology coronary applications cordis endovascular peripheral applications cordis neurovascular neurological applications biosense webster electrophysiology wwwcordiscom medical sensor technology endocardial procedures depuy inc develops markets products depuy ace acromed codmanand mitekbrands depuy depuy ace provide products reconstructing damaged diseased joints repairing reconstructing traumatic skeletal injuries acromed facilitates fusion elements spine correction spinal deformities repairing bone fractures codman provides surgical treatment central nervous system disorders wide range products hydrocephalic shunt valve systems implantable drug pumps micro surgical instrumentation mitek products sports medicine line offers innovative devices wwwdepuycom treatment soft tissue injuries ejnj llc catalyst accelerating adoption ebusiness identification incubation development new webenabled health care business models increase long term growth potential ethicon inc global leader developing marketing products surgery areas wound care wound management womens health cardiovascular surgery advanced wound care treatment products marketed four divisions ethiconproducts offers devices facilitate precise wound closure tissue repair cardiovationspioneers mini mallyinvasive surgical devices help restore improve cardiac health gynecareoffers minimallyinvasive solutions gynecological health problems johnson johnson wound management offers complete line innovative products hemostasis tissue regeneration wwwethiconinccom advanced wound care ethicon endosurgery inc develops markets broad portfolio advanced surgical instru ments less invasive traditional surgery well line safety catheters vascular access mission help physicians around world transform patient care innova tion companys focus designing innovative procedureenabling devices interventional diagnosis treatment various diseases conditions areas general thoracic wwwethiconendocom bariatric surgery breast disease gynecology urology greiter ag develops produces line elegant sunscreen aftersun products combine sun protection special moisturizers products sold throughout europe markets independence technology llc markets products services increase independence people disabilities products include independenceiglidemanual assist wheelchair independencemaxproseat cushion independenceibotmobility system expected approved us wwwindependencenowcom janssencilag companies produce market broad range pharmaceutical products mainly discovered andor developed johnson johnson pharmaceutical research development llc leading products include eprexerypohematology risperdalpsychia try sporanoxdermatologyfungal infections duragesicdurogesicpain management wwwjanssencilagcom topamaxepilepsy parietaciphexgastroenterology reminylalzheimers disease janssen pharmaceutica products lp produces markets prescription medications four thera peutic areas central nervous system disorders gastrointestinal health pain management treatment fungal infections leading products include risperdalrisperidone antipsychot ic aciphexrabeprazole sodium proton pump inhibitor duragesicfentanyl transdermal system skin patch treatment moderate severe pain sporanoxitraconazole wwwjanssencom antifungal reminylgalantamine hydrobromide alzheimers disease primary businesses johnson johnson consumer products company baby care wound care skin care companys wide range products includes familiar line baby child care products complete line family first aid home health care productsskin care products cleansers astringents moisturizers acne treatments body powders wwwjohnsonsbabycom johnson johnson development corporation makes equity investments earlystage venture young publiclytraded health care companies promising new technologies development portfolio companies include fields pharmaceuticals biotechnology medical surgical devices health care information technology diagnostics consumer products johnson johnson gateway llc develops manages webbased resource information created health care professionals johnson johnson medical devices diagnostics companies accessed global internet destination product information clinical content professional education patient materials many countries ecommerce transaction wwwjnjgatewaycom inquiry capabilities johnson johnson health care systems inc provides national managed care government large hospital customers single point contact products johnson johnson domestic companies addition customer account management company offers business support services including contract management supply chain electronic business resources wwwjjhcscom health fitness services employers johnson johnson merck consumer pharmaceuticals co joint venture formed develop market broad range nonprescription products derived primarily merck co inc prescription medicines well products licensed acquired outside sources current products include pepcidac acid controller prevention relief heartburn acid indigestion pepcidcomplete combination acid controller antacid wwwjnjmerckcom mylantaantacid leading line antacidantigas products liquid solid forms johnson johnson pharmaceutical research development llc conducts research development achieves regulatory approval products psychiatry gastroenterology oncology antiinfective central nervous system diabetes hematology immunologyinflammation womens health wound healing wwwjnjpharmarndcom johnson johnson sales logistics company division johnson johnson consumer companies inc provides sales marketing logistical services us retail customers behalf domestic consumer operating companies represents single point contact customers customerfocused selling teams customer service distribution retail merchandis ing professional detailing additionally slc provides leadership emerging global customer base areas transportation enterprisewide systems business processes global customer development lifescan inc dedicated improving quality life people diabetes developing manufacturing marketing wide range blood glucose monitoring systems software use individuals diabetes health care institutions lifescan brands include onetouchbrand consumer products consisting portable electronic meters disposable reagent test strips provide accurate less painful blood glucose readings surestep wwwlifescancom brand institutional systems mcneil consumer specialty pharmaceuticals division mcneilppc inc markets range overthecounter prescription pharmaceuticals including complete lines tylenol acetaminophen motrinib ibuprofen products adults children mcneil otc brands include imodiumad antidiarrheal st josephadult regimen aspirin nizoral ad shampoo prescription products include concertamethylphenidate hcl attention deficit hyperactivity disorder floxinotic ofloxacin otic solution ear infections wwwtylenolcom mcneil comarkets daiichi pharmaceutical corp mcneil nutritionals division mcneilppc inc markets innovative nutritional products dietary alternatives major franchises include benecolcholesterollowering foods supplements lactaidproducts enable lactoseintolerant consumers enjoy dairy foods splendasucralose calorie sweetener broadbased applications viactiv wwwbenecolcom calcium supplementation johnson johnson networking computing services provides broad range networking computing technology products services solutions johnson johnson operating com panies throughout world group also provides leadership optimization enterprise information management infrastructure development emerging infra structure technologies create new business opportunities internal customers neutrogena corporation develops manufactures markets premium high quality skin hair care products sold worldwide recommended medical professionalsthe prod uct line includes bar liquid cleansers shampoo hand cream body lotion facial moisturizers bath preparations cosmetics well hair skin care products orthoneutrogena group company markets skin hair care products recommended used wwwneutrogenacom prescribed dermatologists noramco inc produces variety active pharmaceutical ingredients besides major world wide producer medicinal analgesics pharmaceutical intermediates synthetic fine organic wwwnoramcocom chemicals also produces monomers polymers pharmaceutical medical devices ortho biotech products lp worldwide affiliates market procritepoetin alfa also known eprexand erypooutside us used treat anemia associated specific diseases company also markets orthocloneoktmuromonabcd monoclonal antibody used reverse rejection transplanted organs sporanoxitraconazole difficult totreat lifethreatening fungal infections leustatincladribine hairy cell leukemia duragesicfentanyl transdermal system moderate severe chronic pain cancer patients us ortho biotech markets doxildoxorubicin hcl liposome injection wwworthobiotechcom ovarian cancer kaposis sarcoma orthoclinical diagnostics inc provides professional diagnostic products hospital laboratories commercial clinical laboratories blood donor centers products include reagents used blood transfusions blood screening reagents instrument systems clinical chemistry rhogam injectable drug used prevent hemolytic disease newborn wwworthoclinicalcom orthomcneil pharmaceutical inc provides prescription drugs following categories womens health analgesics antiinfectives antiepileptics urology company pioneer leader area reproductive health leading contraceptive products include ortho tricyclenlo norgestimateethinyl estradiol ortho evra norelgestrominethinyl estradiol first weekly contraceptive patch leading products include ultracettramadol hci pain medication levaquinlevofloxacin antibiotic ditropan xloxybutynin chloride overactive bladder elmironpentosan polysulfate wwworthomcneilcom sodium interstitial cystitis topamaxtopiramate antiepilepsy medication personal products company division mcneilppc inc develops produces markets innovative oral health womens health sanitary protection products leader oral health market full line reachfloss actrinse reachtoothbrush products personal products also leader womens health products monistatvaginal yeast cures kypersonal lubricant uristaturinary pain relief tablets vaginal contraceptives companys comprehensive line sanitary products includes carefreepantiliners ob wwwitsmybodycom tampons stayfreemaxi pads pharmaceutical sourcing group americas division orthomcneil pharmaceutical inc integrates johnson johnson pharmaceutical operations quality assurance organizations within americas thereby enhancing supply chain performance rocis line products care sensitive skin includes lotions cosmetics creams face body anda sun protection line wwwroccom spectacle lens group division johnson johnson vision care inc designs develops manufactures markets innovative spectacle lenses first line products newly patented innovation progressive addition lens market designed meet needs todays presbyopes therakos inc specializes extracorporeal cellbased therapies prevention treatment serious immunemediated neoplastic diseases substantial unmet medical needs therakos proprietary procedures photopheresis currently approved successfully used physicians palliative treatment skin manifestations cutaneous tcell lymphoma additional research way treatment autoimmune disease complications wwwtherakoscom transplantation improved delivery therapy vistakon division johnson johnson vision care inc worlds leading disposable contact lens brand acuvue acuvue surevuebrands marketleading spherical brands day acuvuebrand topselling daily disposable product worldwide acuvue brand bifocal contact lens leading disposable product presbyopes acuvuebrand toric unique lens people astigmatism new acuvue coloursbrand contact lenses wwwjnjvisioncom launched around world offer exceptional comfort handling seven naturallooking colors worldwide family companies united states gynecare lifescaninc somerville new jersey milpitas california advanced sterilization products b schwartz phd worldwide president p b luther president irvine california corsaro president johnson johnson wound management mcneil consumer specialty pharmaceuticals somerville new jersey alza corporation division mcneilppc inc wildman worldwide president mountain view california fort washington pennsylvania h b rosen president ethicon endosurgeryinc w l mccomb president cincinnati ohio babycenterllc mcneil nutritionals r salerno president san francisco california division mcneilppc inc baker general manager independence technologyllc fort washington pennsylvania warren new jersey c f watts president centocorinc jl butel president malvern pennsylvania neutrogena corporation w vernon president janssen pharmaceutica productslp los angeles california titusville new jersey e mcnamara global president cordis corporation gorsky president cardiology orthoneutrogena miami florida johnson johnson skillman new jersey p odwyer worldwide president consumer products company altomari general manager division johnson johnson endovascular consumer companies inc noramcoinc warren new jersey skillman new jersey athens georgia c l zilm worldwide president k dagostino global president r e perkins president skin care biosense webster inc ortho biotech productslp mccoy president diamond bar california bridgewater new jersey babykids wound care g j lebeau md worldwide president g reedy president johnson johnson orthoclinical diagnosticsinc neurovascular developmentcorporation raritan new jersey miami florida new brunswick new jersey rochester new york g j lebeau md worldwide president p holveck president c burzik president depuy johnson johnson gatewayllc orthomcneil pharmaceuticalinc depuy orthopaedics inc piscataway new jersey raritan new jersey warsaw indiana l lee worldwide vice president h z fischer president k k sidow worldwide president johnson johnson health care systemsinc personal products company depuy acromed inc piscataway new jersey division mcneilppc inc raynham massachusetts w barstad president acute care skillman new jersey e r fender worldwide president j martin president e sneed global president managed markets codman shurtleff inc pharmaceutical sourcing group johnson johnsonmerck raynham massachusetts americas consumer pharmaceuticals co g kashuba worldwide president raritan new jersey fort washington pennsylvania c e austin president p k miller president mitek products westwood massachusetts johnson johnson networking spectacle lens group johnson johnson vision careinc r bianchi worldwide president computing services roanoke virginia raritan new jersey ejnjllc j f hogan president shea president north brunswick new jersey therakosinc j hammitt president johnson johnson pharmaceutical research developmentllc exton pennsylvania ethiconinc raritan new jersey r n davis president cardiovations h f weisman md president vistakon division somerville new jersey johnson johnson vision careinc r c coradini worldwide president johnson johnson sales logistics company jacksonville florida ethicon products division johnson johnson casey jr group president somerville new jersey consumer companies inc global franchise americas c e holland worldwide president new brunswick new jersey j colleran president canada mexico czech republic janssencilag farmaceutica janssencilag janssenortho inc sa de cv prague north york ontario mexico city johnson johnson spol sro johnson johnson inc johnson johnson de mexico prague montreal quebec sa de cv denmark mexico city johnson johnson medical products janssencilag markham ontario johnson johnson medical mexico birkerod sa de cv england lifescan canada ltd mexico city cordis uk limited burnaby british columbia panama south ascot mcneil consumer healthcare canada johnson johnson central america depuy international limited guelph ontario panama city leeds ortho biotech peru ethicon endosurgery uk toronto ontario johnson johnson del peru sa bracknell lima orthoclinical diagnostics mississauga ontario puerto rico janssencilag limited johnson johnson caribbean high wycombe vistakon caguas johnson johnson limited markham ontario johnson johnson medical caribbean maidenhead caguas latin america lifescan uk uruguay high wycombe argentina johnson johnson de uruguay sa janssencilag farmaceutica montevideo ortho biotech buenos aires high wycombe venezuela johnson johnson de janssencilag farmaceutica ca orthoclinical diagnostics argentina sa cel caracas amersham buenos aires johnson johnson de venezuela sa vistakon europe johnson johnson medical sa caracas bracknell buenos aires finland brazil europe janssencilag oy janssencilag farmaceutica ltda espoo austria paulo janssencilag gmbh france johnson johnson indstria vienna cordis sa issylesmoulineaux e comrcio ltda johnson johnson gmbh paulo hallein depuy france sa lyon johnson johnson professional johnson johnson medical gmbh products ltda vienna ethicon sa paulo issylesmoulineaux belgium chile janssencilag nv ethicon endosurgery sa johnson johnson de chile sa antwerp issylesmoulineaux santiago colombia janssen pharmaceutica nv janssencilag sa janssencilag farmaceutica sa beerse issylesmoulineaux bogota johnson johnson consumer benelux johnson johnson johnson johnson de colombia sa brussels consumer france sas cali issylesmoulineaux lifescan benelux nv johnson johnson medical colombia beerse lifescan bogota issylesmoulineaux tibotecvirco nv mechelen ortho biotech depuy italy srl scotland issylesmoulineaux milan ethicon limited edinburgh orthoclinical diagnostics sa ethicon spa issylesmoulineaux rome slovenia johnson johnson se germany ethicon endosurgery ljubljana cordis gmbh rome langenfeld spain janssencilag spa janssencilag sa depuy orthopdie gmbh milan madrid sulzbach johnson johnson spa johnson johnson sa ethicon gmbh rome madrid norderstedt lifescan johnson johnson medical ethicon endosurgery milan madrid europe gmbh norderstedt ortho biotech johnson johnsonmerck europe milan madrid janssencilag gmbh rosellen orthoclinical lifescan diagnostics spa madrid johnson johnson gmbh milan dsseldorf orthoclinical diagnostics vistakon madrid lifescan gmbh rome sweden neckargemund netherlands janssencilag ab ortho biotech cordis benelux sollentuna rosellen amersfoort johnson johnson ab orthoclinical diagnostics gmbh janssencilag bv sollentuna neckargemund tilburg johnson johnson consumer vistakon johnson johnsongaba bv products norderstedt almere sollentuna greece johnson johnson medical bv switzerland janssencilag pharmaceutical saci zaventem cilag ag athens schaffhausen norway johnson johnson hellas sa janssencilag greiter ag athens oslo baar johnson johnson poland janssencilag medical products sa janssencilag zug athens warsaw janssencilag ag hungary johnson johnson poland sp zoo baar janssencilag kft warsaw budapest johnson johnson ag portugal spreitenbach johnson johnson kft janssencilag farmaceutica ltda budapest queluz mcneil consumer nutritionals europe zug ireland johnson johnson limitada janssencilag pharmaceutical limited queluz ortho biotech cork baar johnson johnson professional johnson johnson ireland limited products limitada turkey tallaght queluz johnson johnson limited istanbul italy russia cordis spa johnson johnson llc janssencilag milan moscow istanbul asiapacificafrica pt johnson johnson indonesia saudi arabia jakarta johnson johnson saudi arabia australia riyadh depuy australia pty ltd israel nottinghill victoria biosense europe singapore haifa janssencilag singaporemalaysia janssencilag pty ltd singapore north ryde janssencilag kibbutz shefayim johnson johnson medical singapore johnson johnson medical pty ltd singapore north ryde johnson johnson consumer kibbutz shefayim johnson johnson pte ltd johnson johnson pacific pty limited singapore sydney johnson johnson medical kibbutz shefayim orthoclinical diagnostics tasmanian alkaloids pty limited singapore japan westbury tasmania depuy japan inc south africa china tokyo janssencilag pty ltd johnson johnson china ltd sandton shanghai janssen pharmaceutical kk tokyo johnson johnson pty limited johnson johnson medical ltd east london shanghai johnson johnson kk tokyo johnson johnson medical pty ltd shanghai johnson johnson ltd halfway house shanghai johnson johnson medical tokyo taiwan shanghai johnson johnson janssencilag taiwan pharmaceuticals ltd orthoclinical diagnostics kk taipei shanghai tokyo johnson johnson medical taiwan xianjanssen pharmaceutical ltd vistakon japan taipei beijing tokyo johnson johnson taiwan ltd egypt korea taipei johnson johnson egypt sae janssencilag korea ltd cairo seoul thailand janssencilag pharmaceutica limited hong kong johnson johnson korea ltd bangkok janssencilag seoul hong kong johnson johnson asean limited johnson johnson medical korea ltd bangkok johnson johnson hong kong limited seoul hong kong johnson johnson medical thailand malaysia bangkok johnson johnson medical hong kong johnson johnson sdn bhd hong kong selangor darul ehsan united arab emirates johnson johnson middle east inc morocco vistakon dubai johnson johnson morocco sa hong kong casablanca india pakistan janssencilag johnson johnson pakistan mumbai private limited johnson johnson limited karachi mumbai philippines janssencilag philippines johnson johnson professional metro manila mumbai indonesia johnson johnson philippines inc janssencilag pharmaceutica metro manila jakarta corporate shareholderinvestor information principal office common stock dividend reinvestmentplan one johnson johnson plaza listed new york stock exchange plan allows full partial new brunswick new jersey stock symbol jnj dividend reinvestment additional monthly cash investments shareholder relations contact per year johnson johnson stock annual meeting michael h ullmann without brokerage commissions annual meeting shareholders corporate secretary service charges stock purchases take place april hyatt interested joining plan regency new brunswick albany investor relations contact need authorization form andor street new brunswick new jersey helen e short background information please meeting convene vice president investor relations call equiserve trust company na shareholders cordially invited attend formal notice meeting outside us proxy statement proxy sent shareholders transfer agentand registrar hearing impaired questions regarding stock holdings shareholders inquiries regard reports available certificate replacementtransfer ing stockrelated matters communi copies companys annual dividends address changes cate directly equiserve trust report quarterly directed company na via telecommunications reports form q securities equiserve trust company na device tdd telephone number exchange commission p box service annual report available online providence rhode island wwwjnjcom shareholders without outside us charge upon written request outside us secretary companys principal world wide web site office calling internet equiserve home httpwwwjnjcom outside us httpwwwequiservecom following trademarks service marks trade names johnson johnson affiliated companies appear report ace acromed act acuvue acuvue acuvue colours day acuvue aqua aveeno babycentercom bandaid benecol bx velocity cardiovations carefree cidex clean clear codman compeed concerta cordis cypher daktarin definity depuy dermabond ditropan doxil duragesic durogesic durotep ejnj elmiron eprex ergamisol erypo ethicon ethicon endosurgery euroflash floxin global gynecare gynecare intergel gynecare tvt hakim haldol idmicro typing system imodium independence ibot independence iglide independence technology induo ky janssen janssencilag johnson johnson johnsons johnsons ph lactaid lap disc leustatin lifescan mammotome max maxpro mcneil mitek monarch monistat motilium motrin mylanta natusan neutrogena nizoral ob onetouch oros ortho ortho biotech orthoclinical diagnostics orthoclone okt ortho evra orthomcneil orthonovum ortho tricyclen parentcentercom penaten personal products company pinnacle piz buin positively radiant preservation procrit prolene promogran propulsid purpose razor defense reach remicade reminyl reopro retavase retina micro rhogam risperdal risperdal consta roc st joseph shower shower simply cough simply stuffy smartscan splenda sporanox stayfree sterrad stugeron sundown summit surestep surevue surgifoam campaign nursings future topamax tricilest tylenol ultra ultracet ultrasmart uristat viactiv vicryl watchband incision vistakon following trademarks companies also appear report aciphex pariet eisai co ltd levaquin daiichi pharmaceutical co natrecor scios inc pepcid merck co inc together rx together rx llc annual report printed entirety recycled paper johnson johnson credo believe first responsibility doctors nurses patients mothers fathers others use products services meeting needs everything must high quality must constantly strive reduce costs order maintain reasonable prices customers orders must serviced promptly accurately suppliers distributors must opportunity make fair profit responsible employees men women work us throughout world everyone must considered individual must respect dignity recognize merit must sense security jobs compensation must fair adequate working conditions clean orderly safe must mindful ways help employees fulfill family responsibilities employees must feel free make suggestions complaints must equal opportunity employment development advancement qualified must provide competent management actions must ethical responsible communities live work world community well must good citizens support good works charities bear fair share taxes must encourage civic improvements better health education must maintain good order property privileged use protecting environment natural resources final responsibility stockholders business must make sound profit must experiment new ideas research must carried innovative programs developed mistakes paid new equipment must purchased new facilities provided new products launched reserves must created provide adverse times operate according principles stockholders realize fair return one johnson johnson plaza new brunswick new jersey